Bone marrow	1
mesenchymal stromal cells and olfactory ensheathing cells	13
mesenchymal stromal cells	13
olfactory ensheathing cells	43
transplantation after spinal cord injury	71
transplantation	71
spinal cord injury	93
a morphological and functional comparison in rats	114
a morphological and functional comparison	114
rats	159
Abel Torres-Esp ın	165
Abel Torres-Esp	165
ın	181
,1,2 Elena Redondo-Castro ,1,2 Joaquim Hern andez1 ,2 and Xavier Navarro1	183
,1,2 Elena Redondo-Castro ,1,2 Joaquim Hern andez1 ,2	183
Xavier Navarro1	239
,2 1Department of Cell	254
,2 1Department	254
Cell	272
Biology , Physiology and Immunology , Group of Neuroplasticity and Regeneration	277
Biology , Physiology and Immunology , Group	277
Neuroplasticity and Regeneration	322
Institute of Neurosciences , Edif	356
Institute	356
Neurosciences , Edif	369
M	390
Universitat Aut onoma de Barcelona	393
Bellaterra E-08193	429
Spain 2Centro de Investigaci on Biom	449
Spain 2Centro de Investigaci	449
Biom	481
edica en Red sobre Enfermedades Neurodegenerativas -LRB- CIBERNED -RRB-	486
edica en Red sobre	486
Enfermedades Neurodegenerativas -LRB- CIBERNED -RRB-	505
Enfermedades Neurodegenerativas	505
CIBERNED	538
Spain Abstract Cell therapy for spinal cord injury	549
Spain Abstract Cell therapy	549
spinal cord injury	582
SCI	602
a promising strategy for clinical application	610
a promising strategy	610
clinical application	635
Both bone marrow mesenchymal stromal cells	657
MSCs ; also known as bone marrow-derived ` mesenchymal stem cells '	701
MSCs	701
bone marrow-derived ` mesenchymal stem cells '	721
bone marrow-derived	721
mesenchymal stem cells '	742
mesenchymal stem	742
cells '	759
olfactory ensheathing cells	771
OECs	800
beneficial effects following transplantation in animal models of SCI	824
beneficial effects	824
transplantation in animal models of SCI	853
transplantation	853
animal models of SCI	872
animal models	872
SCI	889
the large number	910
parameters	940
the therapy success and the lack of methodological consensus	966
the therapy success	966
the lack of methodological consensus	990
the lack	990
methodological consensus	1002
the comparison of different works	1028
the comparison	1028
different works	1046
we	1087
the effects of MSC and OEC transplants	1099
the effects	1099
MSC and OEC transplants	1114
early or delayed time	1141
a spinal cord contusion injury in the rat	1169
a spinal cord contusion injury	1169
the rat	1203
Functional outcomes	1212
locomotion , sensory perception and electrophysiological responses	1236
locomotion	1236
sensory perception	1248
electrophysiological responses	1271
the grafted cells survival and the amount of cavity and spared tissue	1327
the grafted cells survival	1327
the amount	1358
cavity and spared tissue	1372
cavity	1372
spared tissue	1383
The findings	1411
grafted cells	1438
7 days	1467
the following 2 weeks	1518
the low survival of the cells	1549
the low survival	1549
the cells	1569
MSC and OEC	1580
tissue protection	1608
early and delayed transplantation	1632
only acute MSC grafts	1681
locomotion recovery	1712
treadmill condition and electrophysiological outcomes	1735
treadmill condition	1735
electrophysiological outcomes	1759
respect	1794
the other injured groups	1805
These results , together with previous works ,	1831
These results	1831
previous works	1860
the MSC	1890
a better option	1903
OEC for treatment of contusion injuries	1924
OEC	1924
treatment of contusion injuries	1932
treatment	1932
contusion injuries	1945
Introduction Spinal cord injury -LRB- SCI -RRB-	1966
Introduction Spinal cord injury	1966
Introduction	1966
Spinal cord injury	1979
SCI	1999
partial or complete loss	2013
motor , sensory and autonomic neural functions	2041
the injury level	2093
the damage	2118
local circuitry of the spinal cord	2132
local circuitry	2132
the spinal cord	2151
the interruption of ascending and descending neural pathways	2172
the interruption	2172
neural pathways	2217
the search	2237
potential treatments	2252
repair and recovery	2284
the injury	2309
cell-based therapies	2321
beneficial effects	2360
different types	2385
cells	2404
pre-clinical models	2413
Sykov	2434
a et al. , 2006	2440
a et al.	2440
2006	2450
Sahni & Kessler , 2010	2456
Sahni & Kessler	2456
2010	2473
Hern andez et al. , 2011	2479
Hern andez	2479
et al. , 2011	2490
et al.	2490
2011	2498
Mothe & Tator , 2012	2504
Mothe & Tator	2504
2012	2519
Two	2526
the most	2533
cells	2562
SCI repair	2577
experimental models	2591
good perspectives for clinical translation	2620
good perspectives	2620
clinical translation	2642
bone marrow mesenchymal stromal cells -LRB- MSCs -RRB-	2667
bone marrow mesenchymal stromal cells	2667
MSCs	2706
olfactory ensheathing cells -LRB- OECs -RRB-	2716
olfactory ensheathing cells	2716
OECs	2745
Mesenchymal stromal cells	2752
some degree of functional recovery and tissue protection	2805
some degree	2805
functional recovery and tissue protection	2820
SCI	2868
acute or delayed administration	2875
the spinal cord	2921
Chopp	2938
et al. , 2000	2944
et al.	2944
2000	2952
Hofstetter et al. , 2002	2958
Hofstetter	2958
et al. , 2002	2969
et al.	2969
2002	2977
Neuhuber et al. , 2005	2983
Neuhuber	2983
et al. , 2005	2992
et al.	2992
2005	3000
Himes et al. , 2006	3006
Himes	3006
et al. , 2006	3012
et al.	3012
2006	3020
Amemori et al. , 2010	3026
Amemori	3026
et al. , 2010	3034
et al.	3034
2010	3042
Boido et al. , 2012	3048
Boido	3048
et al. , 2012	3054
et al.	3054
2012	3062
Quertainmont et al. , 2012	3068
Quertainmont	3068
et al. , 2012	3081
et al.	3081
2012	3089
intrathecal injection or intravenous perfusion	3099
Ohta	3147
et al. , 2004 ; Paul et al. , 2009	3152
et al.	3152
2004 ; Paul et al.	3160
2004	3160
Paul et al.	3166
Paul	3166
et al.	3171
2009	3179
The mechanisms underlying the beneficial effects of MSC transplants	3186
The mechanisms	3186
the beneficial effects of MSC transplants	3212
the beneficial effects	3212
MSC transplants	3238
neuroprotection	3266
the expression	3307
neuroprotective molecules	3325
the injured tissue -LRB- Himes et al. , 2006 ; Quertainmont et al. , 2012 -RRB-	3354
the injured tissue	3354
Himes	3374
et al. , 2006 ; Quertainmont et al. , 2012	3380
et al.	3380
2006 ; Quertainmont et al.	3388
2006	3388
Quertainmont et al.	3394
Quertainmont	3394
et al.	3407
2012	3415
modulation	3422
the neuroinflammatory response	3436
Abrams et al. , 2009 ; Nakajima et al. , 2012 ; Torres-Esp ın et al. , 2013	3468
Abrams	3468
et al. , 2009 ; Nakajima et al. , 2012 ; Torres-Esp ın et al. , 2013	3475
et al. , 2009	3475
et al.	3475
2009	3483
Nakajima et al. , 2012	3489
Nakajima	3489
et al. , 2012	3498
et al.	3498
2012	3506
Torres-Esp ın et al. , 2013	3512
Torres-Esp ın	3512
et al. , 2013	3526
et al.	3526
2013	3534
acceleration	3541
the tissue repair process -LRB- Torres-Esp ın et al. , 2013 -RRB-	3557
the tissue repair process	3557
Torres-Esp ın	3584
et al. , 2013	3598
et al.	3598
2013	3606
contribution	3617
a permissive environment	3633
axonal regeneration and neural tissue reconstruction	3662
Hofstetter et al. , 2002 ; Ankeny et al. , 2004 ; Koda et al. , 2007	3716
Hofstetter	3716
et al. , 2002 ; Ankeny et al. , 2004 ; Koda et al. , 2007	3727
et al. , 2002	3727
et al.	3727
2002	3735
Ankeny et al. , 2004	3741
Ankeny	3741
et al. , 2004	3748
et al.	3748
2004	3756
Koda et al. , 2007	3762
Koda	3762
et al. , 2007	3767
et al.	3767
2007	3775
Olfactory ensheathing cells	3782
glial cells present in the olfactory system	3814
glial cells	3814
the olfactory system	3837
Their function	3859
the elongation of newly growing sensory axons	3898
the elongation	3898
newly growing sensory axons	3916
the olfactory epithelium	3949
the central olfactory bulb	3977
axons	4011
new synaptic connections -LRB- Raisman , 1985 ; Doucette , 1995 -RRB-	4022
new synaptic connections	4022
Raisman , 1985 ; Doucette , 1995	4048
Raisman	4048
1985 ; Doucette	4057
1985	4057
Doucette	4063
1995	4073
Acute transplantation of OECs into partial or complete spinal cord lesions	4080
Acute transplantation	4080
OECs into partial or complete spinal cord lesions	4105
OECs	4105
partial or complete spinal cord lesions	4115
the volume of injured tissue	4163
the volume	4163
injured tissue	4177
improvement	4201
functional outcome	4216
axonal regeneration	4248
Li et al. , 1998 ; Lu et al. , 2002 ; Verd u et al. , 2003	4269
Li	4269
et al. , 1998 ; Lu et al. , 2002 ; Verd u et al. , 2003	4272
et al. , 1998	4272
et al.	4272
1998	4280
Lu et al. , 2002	4286
Lu	4286
et al. , 2002	4289
et al.	4289
2002	4297
Verd u et al. , 2003	4303
Verd u	4303
et al. , 2003	4310
et al.	4310
2003	4318
Garc ıa-Al	4324
et al. , 2004 ; L opez-Vales et al. , 2006	4339
et al. , 2004	4339
et al.	4339
2004	4347
L opez-Vales et al. , 2006	4353
L opez-Vales	4353
et al. , 2006	4366
et al.	4366
2006	4374
The proposed mechanisms of action of grafted OECs	4381
The proposed mechanisms	4381
action of grafted OECs	4408
action	4408
grafted OECs	4418
their interaction	4439
astrocytes	4462
Franssen	4474
et al. , 2007 ; Chuah et al. , 2011	4483
et al.	4483
2007 ; Chuah et al.	4491
2007	4491
Chuah et al.	4497
Chuah	4497
et al.	4503
2011	4511
promotion of angiogenesis and modulation of the early neuroinflammatory response	4518
promotion	4518
angiogenesis and modulation	4531
the early neuroinflammatory response	4562
L opez-Vales	4600
et al. , 2004a , b ; Richter et al. , 2005 ; Torres-Esp ın et al. , 2013	4613
et al.	4613
2004a , b ; Richter et al. , 2005 ; Torres-Esp ın et al.	4621
2004a , b	4621
2004a	4621
b	4627
Richter et al. , 2005	4630
Richter	4630
et al. , 2005	4638
et al.	4638
2005	4646
Torres-Esp ın et al.	4652
Torres-Esp ın	4652
et al.	4666
2013	4674
remyelination -LRB- Imaizumi et al. , 1998 -RRB-	4681
remyelination	4681
Imaizumi	4696
et al. , 1998	4705
et al.	4705
1998	4713
axonal regeneration	4734
Li	4755
et al. , 1998 ; L opez - Vales et al. , 2006 , 2007 ; Stamegna et al. , 2011	4758
et al.	4758
1998 ; L opez - Vales et al. , 2006 , 2007 ; Stamegna et al.	4766
1998 ; L opez	4766
1998	4766
L	4772
Vales et al. , 2006 , 2007	4780
Vales	4780
et al. , 2006 , 2007	4786
et al.	4786
2006	4794
2007	4800
Stamegna et al.	4806
Stamegna	4806
et al.	4815
2011	4823
the outcomes found after transplantation of both types of cells	4844
the outcomes	4844
transplantation of both types of cells	4869
transplantation	4869
both types of cells	4888
both types	4888
cells	4902
different findings	4937
the time	4988
transplantation	5000
Hofstetter	5017
et al. , 2002 ; L opez-Vales et al. , 2004a	5028
et al.	5028
2002 ; L opez-Vales et al.	5036
2002	5036
L opez-Vales et al.	5042
L opez-Vales	5042
et al.	5055
2004a	5063
delivery method -LRB- Paul et al. , 2009 -RRB-	5071
delivery method	5071
Paul	5088
et al. , 2009	5093
et al.	5093
2009	5101
type and severity of the injury -LRB- Himes et al. , 2006 -RRB-	5108
type and severity	5108
the injury -LRB- Himes et al. , 2006 -RRB-	5129
the injury	5129
Himes	5141
et al. , 2006	5147
et al.	5147
2006	5155
donor variation -LRB- Phinney et al. , 1999 ; Neuhuber et al. , 2005 -RRB-	5162
donor variation	5162
Phinney	5179
et al. , 1999 ; Neuhuber et al. , 2005	5187
et al.	5187
1999 ; Neuhuber et al.	5195
1999	5195
Neuhuber et al.	5201
Neuhuber	5201
et al.	5210
2005	5218
culture condition of the cells -LRB- Novikova et al. , 2011 -RRB-	5225
culture condition	5225
the cells -LRB- Novikova et al. , 2011 -RRB-	5246
the cells	5246
Novikova	5257
et al. , 2011	5266
et al.	5266
2011	5274
the laboratory	5285
the experiments -LRB- Steward et al. , 2006 ; Franssen et al. , 2007 -RRB-	5311
the experiments	5311
Steward	5328
et al. , 2006 ; Franssen et al. , 2007	5336
et al.	5336
2006 ; Franssen et al.	5344
2006	5344
Franssen et al.	5350
Franssen	5350
et al.	5359
2007	5367
the objective of this work	5385
the objective	5385
this work	5402
the effects on tissue protection	5427
the effects	5427
tissue protection	5442
functional recovery of MSC or OEC transplantation	5464
functional recovery	5464
MSC or OEC transplantation	5487
a contusive SCI	5520
the same animal model , assessment methodologies and culture conditions ,	5543
the same animal model	5543
assessment methodologies and culture conditions	5566
assessment methodologies	5566
culture conditions	5595
the same experimenters	5618
The results	5642
the knowledge	5679
the best option for cell therapy of the contused spinal cord	5706
the best option	5706
cell therapy of the contused spinal cord	5726
cell therapy	5726
the contused spinal cord	5742
the	5742
spinal cord	5755
Materials and methods	5769
Materials	5769
methods	5783
Primary cell cultures	5791
Primary cultures of MSCs and OECs	5813
Primary cultures	5813
MSCs and OECs	5833
P22 male Sprague	5864
Dawley rats	5881
The animals	5894
CO2	5923
each animal	5933
tibias and femurs	5945
MSC culture and the olfactory bulbs	5980
MSC culture	5980
the olfactory bulbs	5996
OEC culture	6020
MSC culture and characterization Tibias and femurs	6033
cool phosphate-buffered saline -LRB- PBS -RRB-	6099
cool phosphate-buffered saline	6099
PBS	6131
epiphyses	6140
The diaphyses of bones	6164
The diaphyses	6164
bones	6181
PBS	6205
a syringe	6215
the marrow	6229
The extract	6257
a 70-µm nylon mesh	6290
centrifugation for 10 min	6326
centrifugation	6326
10 min	6345
220 g	6355
The pellet	6362
growth medium	6392
a-minimum essential medium -LRB- MEM -RRB-	6408
a-minimum essential medium	6408
MEM	6436
L-glutamine	6446
Life Technologies	6459
Grand Island	6478
NY , USA	6492
20 % heat-inactivated fetal bovine serum	6519
20 %	6519
FBS ; Lonza , Verviers , Belgium	6560
FBS	6560
Lonza , Verviers , Belgium	6565
2 mM L-glutamine -LRB- Life Technologies -RRB-	6592
2 mM L-glutamine	6592
Life Technologies	6610
100 units/mL penicillin-streptomycin -LRB- Life Technologies ; 100 9 -RRB-	6633
100 units/mL penicillin-streptomycin	6633
Life Technologies ; 100 9	6671
Life Technologies	6671
100 9	6690
100-mm culture dishes -LRB- Iwaki , Asahi Technoglass , Chiba , Japan -RRB-	6712
100-mm culture dishes	6712
Iwaki	6735
Asahi Technoglass	6742
Chiba , Japan	6761
a density of 5 9	6778
a density	6778
5 9	6791
106 cells/cm2	6795
24 h	6816
the supernatant containing non-adherent cells	6822
the supernatant	6822
non-adherent cells	6849
fresh medium	6884
the culture	6913
confluence , every 4 -- 5 days	6934
confluence , every 4 --	6934
confluence	6934
every 4	6946
5 days	6954
the cells	6962
PBS with 0.05 % trypsin -LRB- Life Technologies -RRB-	6992
PBS	6992
0.05 % trypsin -LRB- Life Technologies -RRB-	7001
0.05 % trypsin	7001
Life Technologies	7016
0.04 % Ethylenediaminetetraacetic acid -LRB- Sigma , St Louis , MO , USA -RRB-	7039
0.04 %	7039
Ethylenediaminetetraacetic acid -LRB- Sigma , St Louis , MO , USA -RRB-	7045
Ethylenediaminetetraacetic acid	7045
Sigma	7078
St Louis	7085
MO , USA	7095
5000 cells/cm2	7122
Cells	7138
three -- four times , expanded to 80 -- 90 % of confluence	7158
three	7158
four times , expanded to 80 -- 90 % of confluence	7164
four times , expanded to 80	7164
four times	7164
80	7188
90 % of confluence	7191
90 %	7191
confluence	7198
phenotype characterization	7214
MSCs after four passages in culture	7242
MSCs	7242
four passages in culture	7253
four passages	7253
culture	7270
30 min	7295
antibodies	7308
CD90 , CD29 , CD11b and CD45	7327
FITC	7371
BD Bioscience , Erembodegem , Belgium	7377
BD Bioscience	7377
Erembodegem , Belgium	7392
1 : 200 v/v	7414
1	7414
200 v/v	7418
incubation	7434
the cells	7446
5 min at 160 g	7477
5 min	7477
160 g	7486
PBS	7511
Analysis of surface markers	7516
Analysis	7516
surface markers	7528
flow citometry -LRB- FACSCalibur , Becton Dickinson -RRB-	7564
flow citometry	7564
FACSCalibur	7580
Becton Dickinson	7593
FACSDiva software -LRB- BD Bioscience -RRB-	7615
FACSDiva software	7615
BD Bioscience	7634
The capacity of the MSC for differentiation to adipogenic and osteogenic cells	7650
The capacity	7650
the MSC for differentiation to adipogenic and osteogenic cells	7666
the MSC	7666
differentiation to adipogenic and osteogenic cells	7678
differentiation	7678
adipogenic and osteogenic cells	7697
et al. , 2008	7775
et al.	7775
2008	7783
analysis of adipogenesis	7794
analysis	7794
adipogenesis	7806
cells	7820
20 min	7841
4 % paraformaldehyde in phosphate buffer	7853
4 % paraformaldehyde	7853
phosphate buffer	7876
the adipogenic cells	7894
60 % Oil red O stock solution -LRB- 0.5 % Oil red O in isopropanol ; Sigma -RRB-	7934
60 % Oil red O stock solution	7934
60 % Oil	7934
red O stock solution	7942
0.5 % Oil red O in isopropanol ; Sigma	7964
0.5 %	7964
Oil red O in isopropanol ; Sigma	7969
Oil red O in isopropanol	7969
Oil red O	7969
isopropanol	7982
Sigma	7995
15 min	8006
distilled water	8029
osteogenic labeling	8050
cells	8071
70 % ethanol pre-cooled for 1 h	8094
70 % ethanol	8094
1 h	8121
4 °C	8128
30 min with 0.1 mg / mL Alizarin red solution -LRB- Sigma -RRB-	8162
30 min	8162
0.1 mg / mL Alizarin red solution -LRB- Sigma -RRB-	8174
0.1 mg / mL Alizarin red solution	8174
mL Alizarin red solution	8182
mL	8182
Alizarin red solution	8185
Sigma	8208
distilled water	8218
OEC culture and characterization Olfactory bulbs	8235
cold Hank 's balanced salt solution -LRB- Sigma -RRB-	8323
cold Hank 's balanced salt solution	8323
cold Hank 's	8323
Sigma	8359
calcium and magnesium	8371
The meningeal layer	8394
a fine forceps	8436
tissue	8456
trypsin	8482
0.25 % ; collagenase A 1 mg/mL ; Becton Dickinson	8490
0.25 %	8490
collagenase A 1 mg/mL	8497
collagenase A	8497
1 mg/mL	8511
Becton Dickinson	8520
DNAsa	8538
I 1 mg/mL ; Roche , Barcelona , Spain	8544
I 1 mg/mL	8544
I	8544
1 mg/mL	8546
Roche , Barcelona , Spain	8555
Roche	8555
Barcelona , Spain	8562
The cells	8610
centrifugation	8638
Dulbecco 's -LRB- D -RRB- MEM nutrient	8656
Dulbecco 's	8656
D	8668
mixture F-12 Ham -LRB- Life Technologies -RRB-	8683
mixture F-12 Ham	8683
Life Technologies	8701
25-cm2 flasks coated with poly-L-lysine and incubated in 5 % CO2 at 37 °C	8736
25-cm2 flasks	8736
poly-L-lysine	8762
5 % CO2 at 37 °C	8793
5 % CO2	8793
37 °C	8803
Culture medium	8810
DMEM supplemented with 10 % FBS -LRB- Life Technologies -RRB-	8829
DMEM	8829
10 % FBS -LRB- Life Technologies -RRB-	8852
10 % FBS	8852
Life Technologies	8861
Cells	8881
culture	8900
7 days	8921
purification	8933
the cells	8947
mouse anti-p75NGFR antibody -LRB- 1 : 100 ; Millipore , Billerica , MA , USA	8977
mouse anti-p75NGFR antibody	8977
1 : 100 ; Millipore , Billerica , MA , USA	9006
1 : 100	9006
Millipore , Billerica , MA , USA	9015
ref	9046
MAB365 -RRB- , then immunopurified with goat antimouse	9051
then immunopurified with goat antimouse	9060
then	9060
goat antimouse	9085
IgG microbeads -LRB- Miltenyi Biotec , Madrid , Spain -RRB-	9100
IgG microbeads	9100
Miltenyi Biotec	9116
Madrid	9133
Spain	9141
the MACS separation -LRB- Miltenyi Biotec -RRB-	9154
the MACS separation	9154
Miltenyi Biotec	9175
OEC purity	9193
at least 75 % determined by immunolabeling against p75 and S100	9208
at least 75 %	9208
immunolabeling against p75 and S100	9235
immunolabeling	9235
p75 and S100	9258
immunocytochemistry	9276
OEC cultures	9297
4 % paraformaldehyde	9326
PBS	9349
30 min	9357
24 h with primary antibodies mouse anti-p75NGFR and rabbit anti-S100	9384
24 h	9384
primary antibodies mouse anti-p75NGFR and rabbit anti-S100	9394
1 : 200 ; DiaSorin , Madrid , Spain	9454
1 : 200	9454
DiaSorin , Madrid , Spain	9463
1 h	9521
secondary antibodies	9530
Cy3-conjugated donkey anti-mouse	9551
1 : 200 ; Jackson ImmunoResearch	9585
1 : 200	9585
Jackson ImmunoResearch	9594
West Grove , PA , USA	9618
West Grove	9618
PA	9630
USA	9634
Alexa 488 donkey anti-rabbit -LRB- 1 : 200 ; Life Technologies -RRB-	9642
Alexa 488 donkey	9642
anti-rabbit -LRB- 1 : 200 ; Life Technologies -RRB-	9659
anti-rabbit	9659
1 : 200 ; Life Technologies	9672
1 : 200	9672
Life Technologies	9681
Cell labeling	9701
identification of the cells after grafting	9719
identification	9719
the cells after grafting	9737
the cells	9737
grafting	9753
we	9763
a green fluorescence protein -LRB- GFP -RRB- lentiviral vector	9771
green fluorescence protein -LRB- GFP -RRB-	9773
green fluorescence protein	9773
GFP	9801
MSCs	9825
a lentiviral vector encoding for GFP under EF1a promoter	9852
a lentiviral vector	9852
GFP	9885
EF1a promoter	9895
Cells in passage 2	9910
Cells	9910
passage 2	9919
2000 cells/cm2	9944
lentiviruses at multiplicity of infection of 10	9978
lentiviruses	9978
multiplicity of infection of 10	9994
multiplicity	9994
infection of 10	10010
infection	10010
10	10023
48 h.	10033
the medium	10045
the cells	10072
OEC transduction	10111
2 -- 3 days of selection	10140
2	10140
3 days of selection	10142
3 days	10142
selection	10152
multiplicity of infection of 50	10165
multiplicity	10165
infection of 50	10181
infection	10181
50	10194
24 h	10201
the medium	10212
complete culture medium and the cells cultured for five more days	10239
complete culture medium	10239
the cells cultured for five more days	10267
the cells	10267
five more days	10290
96 % of transfection	10312
96 %	10312
transfection	10319
efficacy	10332
flow cytometry and fluorescence microscopy counting for both OEC and MSC cells	10359
flow cytometry and fluorescence microscopy	10359
both OEC and MSC cells	10415
SCI and cells transplantation Adult female Sprague -- Dawley rats	10439
SCI	10439
cells transplantation Adult	10447
female Sprague	10475
Dawley rats	10490
Dawley	10490
rats	10497
9 weeks old ; 250 -- 300 g	10503
9 weeks old	10503
250 -- 300 g	10516
250	10516
300 g	10520
The animals	10538
free access	10567
food and water	10582
room temperature of 22 2 °C	10600
room temperature	10600
22 2 °C	10620
The experimental procedures	10631
the ethical committee of the Universitat Aut onoma de Barcelona in accordance	10676
the ethical committee	10676
the Universitat Aut onoma de Barcelona in accordance	10701
the Universitat Aut onoma de Barcelona	10701
accordance	10743
the European Communities Council Directive 86/609/EEC	10759
Operations	10814
ketamine/xylazine anesthesia -LRB- 90/10 mg/kg i.p. -RRB-	10846
ketamine/xylazine anesthesia	10846
90/10 mg/kg	10876
subcutaneous injection of buprenorphine -LRB- 0.05 mg/kg -RRB-	10904
subcutaneous injection	10904
buprenorphine -LRB- 0.05 mg/kg -RRB-	10930
buprenorphine	10930
0.05 mg/kg	10945
the incision site	10960
A longitudinal dorsal incision	10979
T6 -- T10 spinous processes	11029
T6	11029
T10 spinous processes	11032
T10	11032
spinous processes	11036
A laminectomy	11055
T8 -- T9 vertebra	11086
T8	11086
T9 vertebra	11089
a cord contusion of 200 Kdyn	11106
a cord contusion	11106
200 Kdyn	11126
an Infinite Horizon Impactor	11153
Precision System and Instrumentation , Kentucky , USA	11183
Precision System	11183
Instrumentation , Kentucky , USA	11204
the study of treatment effects	11241
the study	11241
treatment effects	11254
the animals	11273
six groups	11303
Three groups of rats	11315
Three groups	11315
rats	11331
30 min after operation	11363
30 min	11363
operation	11376
0 days post-operation -LRB- dpo -RRB- -RSB-	11387
0 days	11387
dpo	11410
vehicle -LRB- VE -- 0 dpo , n = 8 rats -RRB-	11422
vehicle	11422
VE	11431
0 dpo , n = 8 rats	11434
0 dpo	11434
n = 8 rats	11441
n	11441
8 rats	11445
MSC -LRB- MSC -- 0 dpo , n = 8 rats -RRB-	11459
MSC	11459
MSC	11464
0 dpo , n = 8 rats	11468
0 dpo	11468
n = 8 rats	11475
n	11475
8 rats	11479
OEC -LRB- OEC -- 0 dpo , n = 8 rats -RRB-	11495
OEC	11495
OEC	11500
0 dpo , n = 8 rats	11505
0 dpo	11505
n = 8 rats	11512
n	11512
8 rats	11516
Another three groups of rats	11525
Another three groups	11525
rats	11549
7 dpo	11575
vehicle -LRB- VE -- 7 dpo , n = 7 rats -RRB-	11586
vehicle	11586
VE	11595
7 dpo , n = 7 rats	11598
7 dpo	11598
n = 7 rats	11605
n	11605
7 rats	11609
MSC -LRB- MSC -- 7 dpo , n = 7 rats -RRB-	11618
MSC	11618
MSC	11623
7 dpo , n = 7 rats	11627
7 dpo	11627
n = 7 rats	11634
n	11634
7 rats	11638
OEC -LRB- OEC -- 7 dpo , n = 7 rats -RRB-	11649
OEC	11649
OEC	11654
7 dpo , n = 7 rats	11658
7 dpo	11658
n = 7 rats	11665
n	11665
7 rats	11669
assessment of cell localization after grafting	11682
assessment	11682
cell localization after grafting	11696
cell localization	11696
grafting	11720
GFP-labeled cells -LRB- gMSC or gOEC -RRB-	11730
GFP-labeled cells	11730
gMSC or gOEC	11749
gMSC	11749
gOEC	11757
transplanted	11768
acutely or 7 days post-lesion in the corresponding groups gMSC	11788
7 days	11799
the corresponding groups	11821
0 dpo -LRB- n = 9 rats -RRB- , gOEC	11851
0 dpo -LRB- n = 9 rats -RRB-	11851
n	11858
9 rats	11862
gOEC	11871
0 dpo -LRB- n = 9 rats -RRB- , gMSC	11876
0 dpo -LRB- n = 9 rats -RRB-	11876
n	11883
9 rats	11887
gMSC	11896
7 dpo -LRB- n = 9 rats -RRB-	11901
n	11908
9 rats	11912
gOEC -- 7 dpo -LRB- n = 9 rats -RRB-	11924
gOEC	11924
7 dpo -LRB- n = 9 rats -RRB-	11929
n	11936
9 rats	11940
The cells for transplantation	11949
The cells	11949
transplantation	11963
L15 medium -LRB- Life Technologies -RRB- at 50 000 cells/lL	11997
L15 medium -LRB- Life Technologies -RRB-	11997
L15 medium	11997
Life Technologies	12009
50 000 cells/lL	12031
ice	12065
the time of surgery	12076
the time	12076
surgery	12088
The cell viability at the time of injection	12097
The cell viability	12097
the time of injection	12119
the time	12119
injection	12131
90 % , as quantified in a Neubauer chamber using trypan blue stain	12151
90 %	12151
a Neubauer chamber	12173
trypan blue	12198
a glass needle	12223
100 µm	12239
internal diameter ; Eppendorf , Hamburg , Germany	12246
internal diameter	12246
Eppendorf , Hamburg , Germany	12265
a 10-lL Hamilton syringe -LRB- Hamilton # 701 ; Hamilton , Reno , NV , USA -RRB-	12305
a 10-lL Hamilton syringe	12305
Hamilton	12331
# 701 ; Hamilton , Reno , NV , USA	12340
# 701	12340
Hamilton , Reno , NV , USA	12346
3 lL of the corresponding cell suspension or vehicle -LRB- L15 -RRB-	12372
3 lL	12372
the corresponding cell suspension or vehicle -LRB- L15 -RRB-	12380
the corresponding cell suspension or vehicle	12380
L15	12426
the epicenter	12461
2 mm	12482
a total of 450 000 cells per rat	12515
a total	12515
450 000 cells per rat	12526
450 000 cells	12526
rat	12544
A perfusion speed of 2 lL/min	12549
A perfusion speed	12549
2 lL/min	12570
an automatic injector	12597
KDS 310 Plus , Kd Scientific , Holliston , MA , USA	12620
KDS 310 Plus	12620
Kd Scientific	12634
Holliston	12649
MA	12660
USA	12664
the needle tip	12674
the tissue 3 min	12711
each injection to avoid liquid reflux	12734
liquid reflux	12758
The wound	12773
the animals	12799
a warm environment	12833
Bladders	12853
twice a day	12877
reflex voiding of the bladder	12895
reflex voiding	12895
the bladder	12913
infection	12955
amoxicillin -LRB- 500 mg/L -RRB-	12966
amoxicillin	12966
500 mg/L	12979
the drinking water for 1	13002
the drinking water	13002
1	13025
week	13027
Locomotor and sensory function assessment Open-field locomotion Motor behavior	13033
Locomotor	13033
sensory function assessment Open-field locomotion Motor behavior	13047
sensory function assessment	13047
Open-field locomotion Motor behavior	13075
surgery , and at 3 , 7 , 14 , 21 , 28 , 35 and 42 dpo	13130
surgery	13130
3	13146
7	13149
14	13152
21	13156
28	13160
35	13164
42 dpo	13171
Animals	13179
a circular enclosure	13215
5 min	13267
Two observers	13274
locomotion	13298
open-field walking	13316
the hindlimb performance	13347
Basso , Beattie and Bresnahan	13390
BBB	13420
scale	13425
0 -LRB- no movement -RRB-	13445
0	13445
no movement	13448
21 -LRB- normal movement ; Basso et al. , 1995 -RRB-	13464
21	13464
normal movement ; Basso et al. , 1995	13468
normal movement	13468
Basso et al. , 1995	13485
Basso	13485
et al. , 1995	13491
et al.	13491
1995	13499
Treadmill locomotion	13506
The maximal walking speed	13527
gait motion and interlimb coordination	13554
the end time point	13596
treadmill conditions	13635
a Digigait Imaging system	13662
Mouse Specifics	13689
Boston	13706
MA , USA	13714
Redondo-Castro et al. , 2013	13748
Redondo-Castro	13748
et al.	13763
2013	13771
a highspeed video camera	13787
a transparent treadmill belt	13826
ventral images of the animal	13864
ventral images	13864
the animal	13882
140 frames/s	13896
a minimum of eight sequential step cycles	13914
a minimum	13914
eight sequential step cycles	13927
the maximal speed analysis	13975
the treadmill speed	14003
0 cm/s	14056
the animal	14069
the selected speed	14103
gait and interlimb coordination	14127
the animals	14160
20 cm/s	14189
the animals	14206
this speed	14238
The videos	14250
elsewhere -LRB- Redondo-Castro et al. , 2013 -RRB-	14288
elsewhere	14288
Redondo-Castro	14299
et al. , 2013	14314
et al.	14314
2013	14322
The start	14329
times of the stance phase of each step	14350
times	14350
the stance phase of each step	14359
the stance phase	14359
each step	14379
the videos	14417
ImageJ software -LRB- NIH , Bethesda MA , USA -RRB-	14434
ImageJ software	14434
NIH	14451
Bethesda MA	14456
USA	14469
foot gait diagram	14479
McEwen & Springer	14511
2006	14530
Quantitative values	14537
the gait parameters	14561
stride duration , stance duration and swing duration	14582
stride duration	14582
stance duration and swing duration	14599
the stance/swing ratio	14639
a Visual Basic macro for Excel software -LRB- Microsoft -RRB-	14684
a Visual Basic macro	14684
Excel software -LRB- Microsoft -RRB-	14709
Excel software	14709
Microsoft	14726
the values previously extracted	14742
the values	14742
the coordination of locomotion	14785
the coordination	14785
locomotion	14805
the regularity index -LRB- RI -RRB-	14817
the regularity index	14817
RI	14839
A regular step pattern	14859
locomotion , in which each paw is exactly placed one time every four footprints	14908
locomotion , in which each paw is exactly placed one time	14908
locomotion	14908
each paw	14929
one time	14956
every four footprints	14965
a given time	15015
The RI	15029
the percentage of correct step sequences	15053
the percentage	15053
correct step sequences	15071
respect	15099
the total number of step cycles	15110
the total number	15110
step cycles	15130
the lower the RI , the larger	15149
the lower the RI	15149
the lower	15149
the RI	15159
the larger	15167
the number of missteps	15178
the number	15178
missteps	15192
the correct pattern	15215
Cheng et al. , 1997 ; Hamers et al. , 2006	15236
Cheng	15236
et al. , 1997 ; Hamers et al. , 2006	15242
et al. , 1997	15242
et al.	15242
1997	15250
Hamers et al. , 2006	15256
Hamers	15256
et al. , 2006	15263
et al.	15263
2006	15271
Sensory tests	15278
surgery	15314
42 dpo	15329
hindpaws	15344
The rats	15354
the testing chamber for 10 min	15382
the testing chamber	15382
10 min	15406
The response to mechanical stimuli	15414
The response	15414
mechanical stimuli	15430
an electronic Von Frey algesimeter -LRB- Bioseb , Chaville , France -RRB-	15466
an electronic Von Frey algesimeter	15466
Bioseb	15502
Chaville	15510
France	15520
The spring metallic filament connected to a force sensor	15529
The spring metallic filament	15529
a force sensor	15571
the medial part of the hindpaw	15601
the medial part	15601
the hindpaw	15620
the pressure	15633
the threshold	15671
the force at which the animal withdrew the paw	15703
the force	15703
the animal	15722
the paw	15742
The response to heat stimuli	15751
The response	15751
heat stimuli	15767
a Plantar algesimeter -LRB- Ugo Basile , Comerio , Italy -RRB-	15804
a Plantar algesimeter	15804
Ugo Basile	15827
Comerio	15839
Italy	15848
The rats	15856
a radiant hot stimulus	15874
the hindpaw , and the latency time	15900
the hindpaw	15900
the latency time	15917
the animal	15940
the limb	15960
the hot pain threshold	15991
A cut-off time	16015
20 s	16041
tissue damage	16057
Five trials separated by 10-min resting periods for each hindpaw	16072
Five trials	16072
10-min resting periods for each hindpaw	16097
10-min resting periods	16097
each hindpaw	16124
both sensory tests	16155
The value for each test	16175
The value	16175
each test	16189
the mean of both hindpaws	16203
the mean	16203
both hindpaws	16215
Electrophysiological studies	16230
the electrophysiological tests	16263
the animals	16294
30 mg/kg	16344
a metal plate and skin temperature	16378
32 °C	16430
An electromyograph -LRB- Sapphire 4ME , Vickers -RRB-	16437
An electromyograph	16437
Sapphire 4ME	16457
Vickers	16471
Central conduction tests	16490
the evaluation of motorevoked potentials -LRB- MEPs -RRB-	16528
the evaluation	16528
motorevoked potentials -LRB- MEPs -RRB-	16546
motorevoked potentials	16546
MEPs	16570
MEPs	16577
transcranial electrical stimulation of the brain	16599
transcranial electrical stimulation	16599
the brain	16638
Two needle electrodes	16649
the skull , the anode over the sensorimotor cortex and the cathode on the nose	16703
the skull	16703
the anode over the sensorimotor cortex	16714
the anode	16714
the sensorimotor cortex	16729
the cathode on the nose	16757
the cathode	16757
the nose	16772
Single electrical pulses of supramaximal intensity -LRB- 25 mA , 100 ls -RRB-	16782
Single electrical pulses	16782
supramaximal intensity -LRB- 25 mA , 100 ls -RRB-	16810
supramaximal intensity	16810
25 mA	16834
100 ls	16841
the MEPs	16867
monopolar needle electrodes	16895
the tibialis anterior -LRB- TA -RRB-	16928
the tibialis anterior	16928
TA	16951
gastrocnemius medialis -LRB- GM -RRB-	16956
gastrocnemius medialis	16956
plantar -LRB- PL -RRB-	16988
muscles -LRB- Garc ıa-Al ıas et al. , 2004 ; Valero-Cabr e et al. , 2004 -RRB-	17001
muscles	17001
Garc ıa-Al ıas	17010
et al. , 2004 ; Valero-Cabr e et al. , 2004	17025
et al.	17025
2004 ; Valero-Cabr e et al.	17033
2004	17033
Valero-Cabr e et al.	17039
Valero-Cabr	17039
et al.	17053
2004	17061
Peripheral motor nerve conduction tests	17068
the sciatic nerve	17138
single electrical pulses	17161
100 ls at supramaximal intensity	17187
100 ls	17187
supramaximal intensity	17197
needles inserted percutaneously at the sciatic notch	17234
needles	17234
the sciatic notch	17269
the compound muscle action potentials of TA , GM and PL	17302
the compound muscle action potentials	17302
TA , GM and PL	17343
muscles by means of needle electrodes	17357
muscles	17357
means of needle electrodes	17368
means	17368
needle electrodes	17377
The active electrode	17396
the belly of the muscle and the reference	17433
the belly	17433
the muscle and the reference	17446
the muscle	17446
the reference	17461
the fourth toe	17478
The direct M-wave and the reflex H-wave	17494
The direct M-wave	17494
the reflex H-wave	17516
electrophysiological analog of the stretch reflex	17535
electrophysiological analog	17535
the stretch reflex	17566
the same sweep	17603
The peak latency and the onset-to-peak amplitude of the maximal M - and H-waves	17619
The peak latency	17619
the onset-to-peak amplitude of the maximal M - and H-waves	17640
the onset-to-peak amplitude	17640
the maximal M - and H-waves	17671
the maximal M	17671
H-waves	17690
The H/M amplitude ratio	17713
it	17761
an index	17773
the proportion	17785
motor units	17803
the monosynaptic reflex relative	17828
the total pool	17864
spinal motoneurons	17882
Thompson	17902
et al. , 1992 ; Valero-Cabr e et al. , 2004	17911
et al.	17911
1992 ; Valero-Cabr e et al.	17919
1992	17919
Valero-Cabr e et al.	17925
Valero-Cabr	17925
et al.	17939
2004	17947
Histology	17954
Tissue processing	17964
The end time point of the animals for treatment study	17982
The end time point	17982
the animals for treatment study	18004
the animals	18004
treatment study	18020
42 days after injury	18040
42 days	18040
injury	18054
cell tracking	18066
subgroups of animals injected with gMSC or gOEC	18081
subgroups	18081
animals injected with gMSC or gOEC	18094
animals	18094
gMSC or gOEC	18116
7 , 14 and 21	18144
days	18157
injection	18168
n = 3 for each time point	18179
n = 3	18179
n	18179
3	18183
each time point	18189
The rats	18207
pentobarbital 60 mg/kg i.p.	18242
pentobarbital	18242
60 mg/kg i.p.	18256
60 mg/kg	18256
4 % paraformaldehyde in PBS	18304
4 % paraformaldehyde	18304
PBS	18327
The spinal cord segment from 1 cm rostral to 1 cm caudal of the injury epicenter	18332
The spinal cord segment	18332
1 cm rostral to 1 cm caudal of the injury epicenter	18361
1 cm rostral	18361
1 cm caudal of the injury epicenter	18377
1 cm caudal	18377
the injury epicenter	18392
2 cm total length	18414
2 cm	18414
total length	18419
the same fixative solution for 4 h	18465
the same fixative solution	18465
4 h	18496
30 % sucrose	18521
evaluation of the injury	18538
evaluation	18538
the injury	18552
transversal spinal cord sections 30 µm thick	18564
transversal spinal cord sections	18564
30 µm	18597
a cryotome -LRB- Leica CM190 ; Leica Microsystems , Wetzlar , Germany -RRB-	18623
a cryotome	18623
Leica CM190 ; Leica Microsystems	18635
Leica CM190	18635
Leica Microsystems	18648
Wetzlar , Germany	18668
Wetzlar	18668
Germany	18677
15 series of 24 sections -LRB- separated by 450 µm -RRB-	18705
15 series	18705
24 sections -LRB- separated by 450 µm -RRB-	18718
24 sections	18718
450 µm	18744
each	18752
cell survival study	18762
30-µm-thick longitudinal sections of the spinal cord segment	18783
30-µm-thick longitudinal sections	18783
the spinal cord segment	18820
12 series of eight sections -LRB- separated by 360 µm -RRB-	18872
12 series	18872
eight sections -LRB- separated by 360 µm -RRB-	18885
eight sections	18885
360 µm	18914
Sections	18928
gelatincoated glass slides	18957
Hematoxylin-eosin staining	18985
One series of 24 transverse sections	19012
One series	19012
24 transverse sections	19026
5 min in water	19069
5 min	19069
water	19078
hematoxylin Harris solution	19103
the manufacturer 's instructions -LRB- Fluka , Sigma -RRB- for 5 min	19144
the manufacturer 's instructions	19144
the manufacturer 's	19144
Fluka	19177
Sigma	19184
5 min	19195
The tissue sections	19202
water followed by 1 % HCl in ethanol solution for 30 s	19237
water	19237
1 % HCl in ethanol solution for 30 s	19255
1 % HCl	19255
ethanol solution for 30 s	19265
ethanol solution	19265
30 s	19286
The sections	19292
water	19322
Eosin Y -LRB- Merck Millipore , Dramstadt , Germany -RRB- for 6 min	19351
Eosin Y -LRB- Merck Millipore , Dramstadt , Germany -RRB-	19351
Eosin Y	19351
Merck Millipore	19360
Dramstadt	19377
Germany	19388
6 min	19401
The sections	19408
DPX -LRB- Sigma -RRB-	19454
DPX	19454
Sigma	19459
Immunohistochemistry Spinal cord sections of GFP	19467
Immunohistochemistry	19467
Spinal cord sections of GFP	19488
Spinal cord sections	19488
GFP	19512
cell	19517
transplanted rats	19522
immunohistochemistry	19559
GFP -LRB- rabbit anti-GFP ; 1 : 200 ; Life Technologies -RRB- to localize	19588
rabbit anti-GFP	19593
1 : 200 ; Life Technologies	19610
1 : 200	19610
Life Technologies	19619
cells	19660
Other transverse sections	19667
primary antibody	19717
glial fibrillary acidic protein	19742
mouse anti-GFAP	19775
1 : 1000 ; Sigma-Aldrich	19792
1 : 1000	19792
Sigma-Aldrich	19802
astroglial reactivity and the glial scar formed around the lesion	19830
astroglial reactivity	19830
the glial scar formed around the lesion	19856
the glial scar	19856
the lesion	19885
Microglial/macrophage immunoreactivity	19897
antibody	19954
the	19971
calcium-binding adapter molecule 1	19983
calcium-binding adapter molecule	19983
1	20016
rabbit anti-Iba1 , 1	20019
rabbit anti-Iba1	20019
1	20037
1000 ; Wako	20041
1000	20041
Wako	20047
Neuronal survival in the ventral horns	20054
Neuronal survival	20054
the ventral horns	20075
transverse sections	20109
neuronal nuclei -LRB- mouse anti-NeuN ; 1 : 200 ; Millipore -RRB-	20145
neuronal nuclei	20145
mouse anti-NeuN	20162
1 : 200 ; Millipore	20179
1 : 200	20179
Millipore	20188
Tissue sections	20200
PBS	20234
0.3 % Triton and 5 % FBS	20256
0.3 % Triton	20256
5 % FBS	20272
24 h at 4 °C	20298
24 h	20298
4 °C	20306
the corresponding primary antibody	20316
PBS plus 0.3 % Triton and 2.5 % FBS	20362
PBS	20362
0.3 % Triton and 2.5 % FBS	20371
0.3 % Triton	20371
2.5 % FBS	20387
washes	20403
sections	20411
2 h at room temperature	20439
2 h	20439
room temperature	20446
secondary antibody	20468
donkey anti-rabbit AlexaFluor488 for GFP	20488
donkey anti-rabbit AlexaFluor488	20488
GFP	20525
donkey antimouse AlexaFluor594 for GFAP and NeuN	20530
donkey antimouse AlexaFluor594	20530
GFAP and NeuN	20565
donkey anti-rabbit AlexaFluor594 for Iba1 ; 1 : 200 ; Life Technologies	20580
donkey anti-rabbit AlexaFluor594	20580
Iba1 ; 1 : 200 ; Life Technologies	20617
Iba1	20617
1	20623
200	20627
Life Technologies	20632
Slides	20652
Citoseal 60 -LRB- Thermo Fisher Scientific , Madrid , Spain -RRB-	20692
Citoseal 60	20692
Thermo Fisher Scientific	20705
Madrid	20731
Spain	20739
all immunohistochemistry procedures	20750
we	20786
internal controls -LRB- for primary and secondary antibodies -RRB-	20798
internal controls	20798
primary and secondary antibodies	20821
non-specific staining	20865
All the antibodies used in this work	20888
All the antibodies	20888
this work	20915
no labeling	20944
any of the negative controls used	20972
any	20972
the negative controls used	20979
the negative controls	20979
Histological analysis Images	21007
a digital camera	21055
Olympus DP50	21073
the microscope -LRB- Olympus BX51 -RRB-	21099
the microscope	21099
Olympus BX51	21115
Analysis of the GFP + area	21130
Analysis	21130
the GFP + area	21142
the GFP	21142
area	21151
eight spinal cord sections	21176
360 µm between pairs	21217
360 µm	21217
pairs	21232
each animal	21242
Consecutive images of the SCI segment	21255
Consecutive images	21255
the SCI segment	21277
40 9	21307
the same setting	21317
the total section	21338
Photoshop software -LRB- Adobe Systems -RRB-	21374
Photoshop software	21374
Adobe Systems	21394
The microphotographs	21410
ImageJ software	21451
The GFP-labeled area in each section	21468
The GFP-labeled area	21468
each section	21492
a threshold for background correction	21533
a threshold	21533
background correction	21549
Analysis of spared tissue and injury size	21572
Analysis	21572
spared tissue and injury size	21584
19 transversal cord sections	21629
450 µm between pairs	21672
450 µm	21672
pairs	21687
each animal	21697
The transversal section images	21710
40 9	21755
the same setting	21765
The area of spared tissue , cavity and total spinal cord sections	21783
The area	21783
tissue , cavity and total spinal cord sections	21802
ImageJ software	21883
each section	21903
The volume of the graft , spared tissue , cavity and total SCI segment	21917
The volume	21917
the graft , spared tissue , cavity and total SCI segment	21931
the graft	21931
tissue , cavity and total SCI segment	21949
tissue	21949
cavity	21957
total SCI segment	21968
the Cavalieri 's estimator	22007
the Cavalieri 's	22007
morphometric volume -LRB- Rosen & Harry , 1990 -RRB-	22036
morphometric volume	22036
Rosen & Harry	22057
1990	22072
the effects of the cell grafts	22088
the effects	22088
the cell grafts	22103
glial reaction	22122
GFAPand Iba1-labeled areas	22138
three different levels	22182
3 mm rostral from the epicenter	22206
3 mm rostral	22206
the epicenter	22224
the section corresponding to the epicenter	22239
the section	22239
the epicenter	22268
3 mm caudal from the epicenter	22287
3 mm caudal	22287
the epicenter	22304
The analysis of the GFAP + area	22319
The analysis	22319
the GFAP + area	22335
the GFAP	22335
area	22345
both gray and white matter	22362
The labeled area	22390
the fraction with respect	22426
the fraction	22426
respect	22444
the total spinal cord section area	22455
Statistical and data analysis Quantitative data	22491
data analysis	22507
gait analysis , sensory tests and electrophysiology tests	22542
gait analysis	22542
sensory tests	22557
electrophysiology tests	22575
one-way ANOVA	22616
Data of graft volume	22631
Data	22631
graft volume	22639
two-way ANOVA	22672
Statistical analyses of the percentage of spared tissue and BBB score	22687
Statistical analyses	22687
the percentage of spared tissue and BBB score	22711
the percentage	22711
spared tissue and BBB score	22729
spared tissue	22729
BBB score	22747
twoway ANOVA of repeated measures	22775
twoway ANOVA	22775
repeated measures	22791
Bonferroni 's post hoc test for comparative pairs of groups	22810
Bonferroni 's post hoc test	22810
Bonferroni 's	22810
comparative pairs of groups	22841
comparative pairs	22841
groups	22862
all the comparisons	22882
a value of P	22903
a value	22903
P	22914
SEM	22965
Data from maximal treadmill speed	22987
Data	22987
maximal treadmill speed	22997
survival curves	23039
log-rank test	23058
Results Fig. 2 .	23074
Results	23074
Fig. 2	23082
Locomotion test	23090
The open field locomotion	23115
the injury using the BBB score in acute -LRB- A -RRB-	23168
the injury	23168
the BBB score	23185
A	23209
delayed transplantations -LRB- B -RRB-	23216
delayed transplantations	23216
B	23242
injury	23252
all the rats	23259
paralysis of the hindlimbs	23279
paralysis	23279
the hindlimbs	23292
partial recovery during the next 2 -- 3 weeks	23312
partial recovery during the next 2	23312
partial recovery	23312
the next 2	23336
3 weeks	23347
The dotted line	23356
a relevant point	23382
the BBB scale	23402
score of 9 points	23417
score	23417
9 points	23426
the capacity of the rats	23446
the capacity	23446
the rats	23462
body weight	23482
There	23495
slight improvements	23506
the delayed MSC and OEC transplants at 14 days compared with the VE group	23531
the delayed MSC and OEC transplants	23531
14 days compared with the VE group	23570
14 days	23570
the VE group	23592
-LRB- A -RRB- * P < 0.05 VE	23606
-LRB- A -RRB- * P <	23606
-LRB- A -RRB-	23606
P <	23611
0.05 VE	23615
0 dpo and MSC	23623
0 dpo	23623
MSC	23633
0 dpo groups vs. OEC	23637
0 dpo groups	23637
OEC	23654
0 dpo group	23658
0 dpo	23658
group	23664
-LRB- B -RRB- * P < 0.05 OEC	23671
-LRB- B -RRB- * P <	23671
-LRB- B -RRB-	23671
P <	23676
0.05 OEC	23680
7 dpo and MSC	23689
7 dpo	23689
MSC	23699
7 dpo groups vs. VE	23703
7 dpo groups	23703
VE	23720
7 dpo group	23723
7 dpo	23723
group	23729
The percentage of animals that were able to run at increasing treadmill speeds	23736
The percentage	23736
animals that were able to run at increasing treadmill speeds	23754
animals	23754
increasing treadmill speeds	23787
survival curves -LRB- C and D -RRB-	23831
survival curves	23831
C and D	23848
C	23848
D	23854
The P-value for each comparison	23858
The P-value	23858
each comparison	23874
the statistical significance of the log-rank test	23901
the statistical significance	23901
the log-rank test	23933
The gait performance during treadmill walking	23952
The gait performance	23952
treadmill walking	23980
the stance/swift ratio	24017
all the SCI animals	24050
similar disturbances -LRB- E and F , left panels -RRB-	24077
similar disturbances	24077
E and F ,	24099
E	24099
F	24105
panels	24113
The interlimb coordination , assessed using the RI ,	24122
The interlimb coordination	24122
the RI	24165
marked reduction	24180
all the injured rats -LRB- E and F , right panel -RRB-	24200
all the injured rats	24200
E and F , right panel	24222
E and F	24222
right panel	24231
-LRB- E and F -RRB- * P < 0.05 SCI groups vs. intact control rats	24245
-LRB- E and F -RRB-	24245
E	24246
F	24252
P <	24256
0.05	24260
SCI groups vs. intact control rats	24265
SCI groups	24265
intact control rats	24280
Fig. 2 .	24302
Fig.	24302
2	24307
Locomotion test	24310
The open field locomotion	24335
the injury using the BBB score in acute -LRB- A -RRB-	24388
the injury	24388
the BBB score	24405
A	24429
delayed transplantations -LRB- B -RRB-	24436
delayed transplantations	24436
B	24462
injury	24472
all the rats	24479
paralysis of the hindlimbs	24499
paralysis	24499
the hindlimbs	24512
partial recovery during the next 2 -- 3 weeks	24532
partial recovery during the next 2	24532
partial recovery	24532
the next 2	24556
3 weeks	24567
The dotted line	24576
a relevant point	24602
the BBB scale	24622
score of 9 points	24637
score	24637
9 points	24646
the capacity of the rats	24666
the capacity	24666
the rats	24682
body weight	24702
There	24715
slight improvements	24726
the delayed MSC and OEC transplants at 14 days compared with the VE group	24751
the delayed MSC and OEC transplants	24751
14 days compared with the VE group	24790
14 days	24790
the VE group	24812
-LRB- A -RRB- * P < 0.05 VE	24826
-LRB- A -RRB- * P <	24826
-LRB- A -RRB-	24826
P <	24831
0.05 VE	24835
0 dpo and MSC	24843
0 dpo	24843
MSC	24853
0 dpo groups vs. OEC	24857
0 dpo groups	24857
OEC	24874
0 dpo group	24878
0 dpo	24878
group	24884
-LRB- B -RRB- * P < 0.05 OEC	24891
-LRB- B -RRB- * P <	24891
-LRB- B -RRB-	24891
P <	24896
0.05 OEC	24900
7 dpo and MSC	24909
7 dpo	24909
MSC	24919
7 dpo groups vs. VE	24923
7 dpo groups	24923
VE	24940
7 dpo group	24943
7 dpo	24943
group	24949
The percentage of animals that were able to run at increasing treadmill speeds	24956
The percentage	24956
animals that were able to run at increasing treadmill speeds	24974
animals	24974
increasing treadmill speeds	25007
survival curves -LRB- C and D -RRB-	25051
survival curves	25051
C and D	25068
C	25068
D	25074
The P-value for each comparison	25078
The P-value	25078
each comparison	25094
the statistical significance of the log-rank test	25121
the statistical significance	25121
the log-rank test	25153
The gait performance during treadmill walking	25172
The gait performance	25172
treadmill walking	25200
the stance/swift ratio	25237
all the SCI animals	25270
similar disturbances -LRB- E and F , left panels -RRB-	25297
similar disturbances	25297
E and F ,	25319
E	25319
F	25325
panels	25333
The interlimb coordination , assessed using the RI ,	25342
The interlimb coordination	25342
the RI	25385
marked reduction	25400
all the injured rats -LRB- E and F , right panel -RRB-	25420
all the injured rats	25420
E and F , right panel	25442
E and F	25442
right panel	25451
-LRB- E and F -RRB- * P < 0.05 SCI groups vs. intact control rats	25465
-LRB- E and F -RRB-	25465
E	25466
F	25472
P <	25476
0.05	25480
SCI groups vs. intact control rats	25485
SCI groups	25485
intact control rats	25500
Fig. 3 .	25522
Fig.	25522
3	25527
Sensory test results .	25530
Sensory test	25530
results	25543
The responses	25552
noxious mechanical stimulus	25569
an electronic Von Frey device -LRB- A and B -RRB-	25612
an electronic Von Frey device	25612
A and B	25643
A	25643
B	25649
heat stimulus using the Plantar test -LRB- C and D -RRB-	25659
heat stimulus	25659
the Plantar test -LRB- C and D -RRB-	25679
the Plantar test	25679
C and D	25697
C	25697
D	25703
The threshold values	25707
percentages with respect	25747
percentages	25747
respect	25764
pre-operative values for each treatment group	25775
pre-operative values	25775
each treatment group	25800
the injury	25828
the thresholds of both sensory tests	25840
the thresholds	25840
both sensory tests	25858
all treatment conditions	25893
hypersensitivity in front	25930
hypersensitivity	25930
front	25950
noxious mechanical and thermal stimuli	25959
No differences	25999
acute or delayed transplant groups	26036
Fig. 4 .	26073
Fig.	26073
4	26078
Electrophysiological results	26081
Compound muscle action potential	26111
Compound muscle action	26111
plantar -LRB- PL -RRB- muscle before	26156
plantar -LRB- PL -RRB- muscle	26156
PL	26165
A , left panel	26184
A	26184
panel	26192
after -LRB- A , right panel -RRB- SCI	26203
after	26203
A , right panel	26210
A	26210
right panel	26213
SCI	26226
SCI	26237
no changes	26241
the amplitude of the M-wave	26269
the amplitude	26269
the M-wave	26286
the H-wave	26302
The increased H/M ratio after injury	26324
The increased H/M ratio	26324
injury	26354
hyper-reflexia in the spinal segments	26371
hyper-reflexia	26371
the spinal segments	26389
the damage	26415
The H/M ratio	26427
both acute and delayed MSC groups compared with OEC and VE groups -LRB- B -RRB-	26458
both acute and delayed MSC groups	26458
OEC and VE groups -LRB- B -RRB-	26506
OEC and VE groups	26506
B	26525
Representative	26529
recordings of MEPs of the tibialis	26544
recordings	26544
MEPs of the tibialis	26558
MEPs	26558
the tibialis	26566
anterior -LRB- TA -RRB- muscle before injury -LRB- C -RRB-	26579
anterior -LRB- TA -RRB- muscle	26579
TA	26589
injury -LRB- C -RRB-	26607
injury	26607
C	26615
injury and VE injection -LRB- D -RRB-	26625
injury and VE injection	26625
D	26650
injury and MSC injection -LRB- E -RRB-	26664
injury and MSC injection	26664
E	26690
intact rats	26697
MEPs	26709
a latency of about 6 ms -LRB- C , with arrow -RRB-	26718
a latency	26718
6 ms -LRB- C , with arrow -RRB-	26737
6 ms	26737
C , with arrow	26743
C	26743
arrow	26751
injury	26765
this early response	26772
a second slower response	26809
a latency of about 20 ms -LRB- D and E , black arrow -RRB-	26852
a latency	26852
about 20 ms -LRB- D and E , black arrow -RRB-	26865
about 20 ms	26865
D and E , black arrow	26878
D and E	26878
black arrow	26887
The amplitude	26901
the late MEP component	26918
the percentage	26945
animals that presented this response from TA	26963
animals	26963
this response	26986
TA	27005
gastrocnemius medialis -LRB- GM -RRB- muscles	27012
gastrocnemius medialis	27012
muscles	27040
the acute -LRB- F and H , respectively -RRB-	27068
the acute	27068
F and H , respectively	27079
F and H	27079
-LRB- G and I , respectively -RRB- treatments	27114
G and I , respectively	27115
G and I	27115
G	27115
I	27121
B and C	27151
B	27151
C	27157
P	27161
0.05 injured groups vs. intact rats ; # P < 0.05 MSC group vs. OEC and VE groups	27165
0.05 injured groups	27165
intact rats ; # P < 0.05 MSC group vs. OEC and VE groups	27189
intact rats	27189
# P < 0.05 MSC group vs. OEC and VE groups	27202
# P < 0.05 MSC group	27202
# P <	27202
0.05 MSC group	27207
OEC and VE groups	27226
-LRB- A -RRB- Vertical bar = 2 mV	27245
-LRB- A -RRB- Vertical bar	27245
A	27246
2 mV	27264
horizontal bar	27270
= 2 ms. -LRB- C -RRB- Vertical bar	27285
2	27287
C	27294
= 10 mV	27310
10	27312
horizontal bar	27319
= 5 ms. -LRB- D and E -RRB- Vertical bar	27334
5	27336
D and E	27343
D	27343
E	27349
= 50 lV ; horizontal bar = 5 ms. Fig. 5	27365
= 50 lV	27365
50	27367
horizontal bar = 5 ms. Fig. 5	27374
horizontal bar = 5 ms. Fig.	27374
Histological analysis .	27406
The analysis	27429
acute -LRB- A -RRB-	27467
acute	27467
A	27474
B	27490
transplantation	27493
SCI	27515
The amount of protected tissue	27520
The amount	27520
protected tissue	27534
the percentage	27570
tissue area	27595
respect	27612
the total area of the section	27623
the total area	27623
the section	27641
The measures	27654
hematoxylin-eosinstained transversal sections -LRB- A and B , bottom panel -RRB-	27680
hematoxylin-eosinstained transversal sections	27680
A and B , bottom panel	27727
A and B	27727
bottom panel	27736
the injured spinal cord segment at 6 weeks	27753
the injured spinal cord segment	27753
6 weeks	27788
SCI	27802
The comparison between acute and delayed treatment	27807
The comparison	27807
acute and delayed treatment	27830
the percentage	27879
spared volume -LRB- C -RRB- of vehicle -LRB- C , left panel -RRB-	27897
spared volume -LRB- C -RRB- of vehicle	27897
spared volume -LRB- C -RRB-	27897
spared volume	27897
C	27912
vehicle	27918
C , left panel	27927
C	27927
panel	27935
MSC -LRB- C , center panel -RRB- and OEC -LRB- C , right panel -RRB- groups	27943
MSC -LRB- C , center panel -RRB-	27943
MSC	27943
C , center panel	27948
C	27948
center panel	27951
OEC -LRB- C , right panel -RRB- groups	27969
OEC	27969
C , right panel	27974
C	27974
right panel	27977
groups	27990
The results	27998
tissue protection	28015
both MSC and OEC transplantation	28038
MSC	28043
OEC transplantation	28051
acute and delayed treatment	28079
differences between them	28120
differences	28120
them	28140
P	28147
< 0.05 MSC group	28149
<	28149
0.05 MSC group	28151
VE group	28170
# P <	28180
# P	28180
<	28183
0.05 OEC	28185
group vs. VE	28194
group	28194
VE	28204
group	28207
Fig. 6 .	28215
Fig.	28215
6	28220
Neuronal survival after SCI and cell transplantation .	28223
Neuronal survival	28223
SCI and cell transplantation	28247
SCI	28247
cell transplantation	28255
the end point	28280
immunohistochemistry against NeuN	28295
immunohistochemistry	28295
NeuN	28324
transversal spinal cord sections -LRB- A -RRB-	28346
transversal spinal cord sections	28346
A	28380
the ventral horn	28387
these sections -LRB- A , below dotted line -RRB-	28407
these sections	28407
A , below dotted line	28423
A	28423
dotted line	28432
the number of NeuN + cells -LRB- A , inset -RRB- was counted	28446
the number	28446
NeuN + cells -LRB- A , inset -RRB- was counted	28460
NeuN + cells -LRB- A , inset -RRB-	28460
NeuN + cells	28460
A , inset	28473
A	28473
Counts	28496
sections from 4 mm rostral	28516
sections	28516
4 mm rostral	28530
4 mm caudal	28546
the lesion epicenter	28561
the analysis	28587
acute -LRB- B -RRB-	28625
acute	28625
B	28632
C	28648
transplantation	28651
SCI	28673
The results	28678
a higher number of NeuN + cells in both MSC and OEC transplantation	28695
a higher number	28695
NeuN + cells in both MSC and OEC transplantation	28714
NeuN + cells	28714
both MSC and OEC transplantation	28729
MSC	28734
OEC transplantation	28742
both acute and delayed injection	28768
P	28804
0.01	28808
P	28818
0.05 MSC group	28822
VE group ; & & & P < 0.001 , & & P < 0.01 and & P < 0.05 OEC group vs. VE group	28841
VE group ; & & & P < 0.001 , & & P < 0.01	28841
VE group ; & & & P < 0.001	28841
VE group	28841
&	28851
& & P < 0.001	28852
& P < 0.001	28853
& P <	28853
& P	28853
0.001	28858
& P < 0.01	28866
& P <	28866
& P	28866
0.01	28871
& P < 0.05 OEC group vs. VE group	28880
& P <	28880
& P	28880
<	28883
0.05 OEC group vs. VE group	28885
0.05 OEC group	28885
VE group	28904
Scale bar : 400 µm -LRB- A -RRB- ; 50 µm -LRB- A inset -RRB- .	28914
Scale bar : 400 µm -LRB- A -RRB-	28914
Scale bar	28914
400 µm -LRB- A -RRB-	28925
A	28933
50 µm -LRB- A inset -RRB-	28937
50 µm	28937
A inset	28944
A	28944
Fig. 7 .	28955
Fig.	28955
7	28960
Astroglial reactivity after SCI and cell transplantation .	28963
Astroglial reactivity	28963
SCI and cell transplantation	28991
SCI	28991
cell transplantation	28999
the end point	29024
immunohistochemistry against GFAP	29039
immunohistochemistry	29039
GFAP	29068
the amount of astrocytes in transversal spinal cord sections -LRB- A -RRB-	29094
the amount	29094
astrocytes in transversal spinal cord sections -LRB- A -RRB-	29108
astrocytes	29108
transversal spinal cord sections -LRB- A -RRB-	29122
transversal spinal cord sections	29122
A	29156
The percentage of GFAP + immunostained area	29160
The percentage	29160
GFAP + immunostained area	29178
GFAP	29178
immunostained area	29184
both gray -LRB- A1 -RRB- and white -LRB- A2 and A3 -RRB- matter	29221
gray -LRB- A1 -RRB-	29226
white -LRB- A2 and A3 -RRB- matter	29240
A2 and A3	29247
A2	29247
A3	29254
spinal cord sections	29269
3 mm rostral and 3 mm caudal	29307
3 mm rostral	29307
3 mm caudal	29324
the epicenter	29339
the epicenter	29366
The analysis	29381
acute -LRB- B -RRB-	29419
acute	29419
B	29426
C	29442
transplantation	29445
SCI	29467
both -LRB- B -RRB- and -LRB- C -RRB-	29475
both -LRB- B -RRB-	29475
-LRB- C -RRB-	29488
the left graphs	29493
the white mater and the right graphs the gray matter measurements	29519
the white mater	29519
the right graphs the gray matter measurements	29539
the right graphs	29539
the gray matter measurements	29556
The results	29586
an increase of GFAP	29603
an increase	29603
GFAP	29618
positive area	29624
the epicenter compared with both rostral and caudal sections	29641
the epicenter	29641
both rostral and caudal sections	29669
both rostral	29669
caudal sections	29686
any difference between groups	29715
any difference	29715
groups	29738
Scale bar : 400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 and A3 -RRB- .	29746
Scale bar	29746
400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 and A3 -RRB-	29757
400 µm -LRB- A -RRB-	29757
A	29765
50 µm -LRB- A1 , A2 and A3 -RRB-	29769
A1 , A2 and A3	29776
A1	29776
A2 and A3	29780
C , section 3 mm caudal to the epicenter	29792
C	29792
section 3 mm caudal to the epicenter	29795
section 3 mm caudal	29795
the epicenter	29818
E , epicenter section	29833
E	29833
epicenter section	29836
R , section 3 mm rostral to the epicenter	29855
R	29855
section 3 mm rostral to the epicenter	29858
section 3 mm rostral	29858
the epicenter	29882
Fig. 8 .	29898
Fig.	29898
8	29903
Microglial/macrophages	29906
SCI and cell transplantation	29946
SCI	29946
cell transplantation	29954
the end point	29979
immunohistochemistry against Iba1	29994
immunohistochemistry	29994
Iba1	30023
the amount	30049
microglial/macrophages reactivity	30063
transversal spinal cord sections -LRB- A -RRB-	30100
transversal spinal cord sections	30100
A	30134
The percentage of Iba1 + immunostained area	30138
The percentage	30138
Iba1 + immunostained area	30156
Iba1	30156
immunostained area	30162
the white mater -LRB- A1 and A2 -RRB-	30197
the white mater	30197
A1 and A2	30214
A1	30214
A2	30221
The analysis	30226
spinal cord sections	30256
3 mm rostral and 3 mm caudal	30294
3 mm rostral	30294
3 mm caudal	30311
the epicenter	30326
the epicenter	30353
The analysis	30368
acute -LRB- B -RRB-	30406
acute	30406
B	30413
C	30429
transplantation	30432
SCI	30454
The results	30459
a reduction in Iba1-immunostained area in caudal sections	30480
a reduction	30480
Iba1-immunostained area in caudal sections	30495
Iba1-immunostained area	30495
caudal sections	30522
MSC or OEC acute transplantation	30544
MSC	30544
OEC acute transplantation	30551
the case of delayed cell injection	30581
the case	30581
delayed cell injection	30593
a reduction in Iba1-immunostained area	30617
a reduction	30617
Iba1-immunostained area	30632
both rostral and caudal sections	30672
rostral	30677
caudal sections	30689
MSC or OEC transplantation	30711
There	30739
no significant changes at the epicenter in any experimental condition	30750
no significant changes	30750
the epicenter in any experimental condition	30776
the epicenter	30776
any experimental condition	30793
Scale bar : 400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 -RRB- .	30821
Scale bar	30821
400 µm -LRB- A -RRB- ; 50 µm -LRB- A1 , A2 -RRB-	30832
400 µm -LRB- A -RRB-	30832
A	30840
50 µm -LRB- A1 , A2 -RRB-	30844
A1 , A2	30851
A1	30851
A2	30855
C , section 3 mm caudal to epicenter	30860
C	30860
section 3 mm caudal to epicenter	30863
section 3 mm caudal	30863
epicenter	30886
E , epicenter section	30897
E	30897
epicenter section	30900
R , section 3 mm rostral to epicenter	30919
R	30919
section 3 mm rostral to epicenter	30922
section 3 mm rostral	30922
epicenter	30946
P	30958
0.05 MSC and OEC groups vs. VE group	30962
0.05 MSC and OEC groups	30962
VE group	30990
Graft survival	31001
the spinal cord One week after transplantation , the GFP + cells	31021
the spinal cord	31021
One week	31037
transplantation , the GFP + cells	31052
transplantation	31052
the GFP	31069
cells	31078
the epicenter of the injury	31107
the epicenter	31107
the injury	31124
the rostral and caudal injection sites -LRB- Fig. 1A -RRB-	31145
the rostral	31145
caudal injection sites -LRB- Fig. 1A -RRB-	31161
caudal injection sites	31161
Fig. 1A	31185
A strong reduction of the amount of GFP	31195
A strong reduction	31195
the amount of GFP	31217
the amount	31217
GFP	31231
2 weeks	31251
3 weeks	31274
all groups -LRB- Fig. 1B -- D -RRB-	31300
all groups	31300
Fig. 1B -- D	31312
Fig. 1B	31312
D	31320
a significant main effect of time	31330
a significant main effect	31330
time	31359
two-way ANOVA	31377
MSC grafting -LRB- F2 ,12 = 106.81 , P < 0.0001 ; Fig. 1E -RRB-	31397
MSC grafting	31397
F2 ,12 = 106.81 , P	31411
F2 ,12	31411
106.81 , P	31419
106.81	31419
P	31427
0.0001 ; Fig. 1E	31431
0.0001	31431
Fig. 1E	31439
OEC grafting -LRB- F2 ,12 = 48.29 , P < 0.0001 ; Fig. 1F -RRB-	31452
OEC grafting	31452
F2 ,12 = 48.29 , P < 0.0001 ; Fig. 1F	31466
F2 ,12 = 48.29	31466
F2 ,12	31466
48.29	31474
P < 0.0001 ; Fig. 1F	31481
P < 0.0001	31481
P	31481
0.0001	31485
Fig. 1F	31493
Fig.	31493
1F	31498
the GFP + volume	31509
the GFP	31509
volume	31518
delayed gMSC grafting at 1 week after injection	31553
delayed gMSC	31553
1 week after injection	31578
1 week	31578
injection	31591
the decrease from 7 to 14 days after injection	31602
the decrease	31602
7 to 14 days after injection	31620
7 to 14 days	31620
injection	31639
delayed gMSC transplants	31686
two-way ANOVA interaction F2 ,12 = 24.44 , P < 0.0001 ; Fig. 1E	31712
two-way ANOVA interaction	31712
F2 ,12	31738
24.44 , P < 0.0001 ; Fig. 1E	31746
24.44	31746
P < 0.0001 ; Fig. 1E	31753
P < 0.0001	31753
P	31753
0.0001	31757
Fig. 1E	31765
Fig.	31765
1E	31770
A similar result	31775
14 days	31808
gOEC transplantation	31822
lower GFP	31849
volume	31859
delayed transplants -LRB- Fig. 1F -RRB-	31896
delayed transplants	31896
Fig. 1F	31917
statistical significance	31939
the gMSC	31975
gOEC after acute -LRB- Fig. 1G -RRB- or delayed -LRB- Fig. 1H -RRB- treatment	31988
acute -LRB- Fig. 1G -RRB-	31999
acute	31999
Fig. 1G	32006
Fig. 1H	32027
no significant differences	32047
a similar GFP signal reduction	32090
both types of cells	32140
both types	32140
cells	32154
These observations	32161
the survival of grafted cells	32194
the survival	32194
grafted cells	32210
time	32248
2 weeks	32276
the transplant	32290
acute transplantation of the cells	32320
acute transplantation	32320
the cells	32345
their survival	32369
delayed injection	32389
Locomotor function	32408
The BBB open field locomotion score	32427
the gross voluntary locomotion activity	32480
SCI	32526
all the injured groups	32534
there	32557
paralysis	32567
the hindlimbs -LRB- 0 score -RRB-	32580
the hindlimbs	32580
0 score	32595
3 days post-injury , followed by recovery during the next 2 weeks	32607
3 days post-injury	32607
recovery	32639
the next 2 weeks	32655
Fig. 2A and B	32673
Fig. 2A	32673
B	32685
The animals	32689
a plateau	32710
significant recovery	32728
the last 3 weeks of follow-up	32756
the last 3 weeks	32756
follow-up	32776
a BBB score of about 10 -- 11 points	32791
a BBB score of about 10	32791
a BBB score	32791
10	32812
11 points	32815
the early phase	32833
there	32850
only a few differences between groups	32861
only a few differences	32861
groups	32892
the acute MSC transplant and the vehicle groups	32900
the acute MSC transplant	32900
the vehicle groups	32929
higher BBB score	32955
the OEC transplant group	32977
VE	33013
0 dpo	33016
OEC	33026
7 dpo	33030
Bonferroni t = 2.95 , P < 0.05	33037
Bonferroni t = 2.95 , P <	33037
Bonferroni t	33037
= 2.95 , P <	33050
2.95 , P	33052
2.95	33052
P	33058
0.05	33062
MSC	33068
0 dpo vs. OEC	33072
0 dpo	33072
OEC	33082
7 dpo	33087
Bonferroni t = 2.92	33094
Bonferroni t	33094
2.92	33109
P < 0.01 ; Fig. 2A	33115
P < 0.01	33115
P <	33115
P	33115
0.01	33119
Fig. 2A	33125
Fig.	33125
2A	33130
both subacute cell transplants	33143
higher scores than vehicle	33178
higher scores	33178
vehicle	33197
14 days	33208
VE	33217
7 dpo	33220
MSC	33230
7 dpo	33234
Bonferroni t = 3.27 , P < 0.05	33241
Bonferroni t = 3.27 , P <	33241
Bonferroni t	33241
= 3.27 , P <	33254
3.27 , P	33256
3.27	33256
P	33262
0.05	33266
VE	33272
7 dpo vs. OEC	33276
7 dpo	33276
OEC	33286
7 dpo	33290
Bonferroni t = 3.29	33297
Bonferroni t	33297
3.29	33312
P < 0.01 ; Fig. 2B	33318
P < 0.01	33318
P <	33318
P	33318
0.01	33322
Fig. 2B	33328
Fig.	33328
2B	33333
No significant differences	33338
the acute	33384
the subacute	33398
groups	33420
the plateau phase	33434
Digigait Non-injured animals	33453
maximal treadmill speed about 80 cm/s	33502
maximal treadmill speed	33502
80 cm/s	33532
all injured groups	33544
the rats	33564
their weight	33583
stance	33599
all	33610
5 cm/s treadmill speed	33634
acute treatment	33661
significantly more rats of the MSC group	33677
significantly more rats	33677
the MSC group	33704
higher speeds	33750
the groups OEC	33772
VE	33791
log-rank test , P-value 0.008 and 0.04 , respectively	33795
log-rank test , P-value 0.008 and 0.04	33795
log-rank test	33795
0.008 and 0.04	33818
a higher median speed -LRB- MSC --	33854
a higher median speed	33854
MSC	33877
0 dpo	33881
37.5 cm/s	33888
OEC	33899
0 dpo	33903
30 cm/s	33910
VE	33919
0 dpo	33923
20 cm/s	33930
Fig. 2C	33939
No statistical differences	33949
OEC and VE acute groups	33998
subacute treatment	34028
no significant differences	34048
the three groups	34094
the MSC transplant	34121
the other two groups	34171
The analysis of the gait parameters and interlimb coordination	34193
The analysis	34193
the gait parameters and interlimb coordination	34209
20 cm/s treadmill speed -LRB- Redondo-Castro et al. , 2013 -RRB-	34274
20 cm/s treadmill speed	34274
Redondo-Castro	34299
et al. , 2013	34314
et al.	34314
2013	34322
SCI	34335
the animals	34340
the forelimb step	34362
the hindlimb step number	34392
a consequence	34421
the stance and swing time for each step	34436
the stance and swing time	34436
each step	34466
forelimbs	34489
the stance time	34506
hindlimbs	34535
These changes	34546
the stance/swing ratio	34578
both fore - and hindlimbs	34620
both fore	34620
hindlimbs	34635
the injury in comparison	34651
the injury	34651
comparison	34665
intact rats	34681
There	34694
no significant differences	34705
treatment groups	34740
the gait parameters	34760
two-way ANOVA : F3 ,50 = 8.39 , P = 0.0001 ; Fig. 2E ,	34781
two-way ANOVA	34781
F3 ,50 = 8.39	34796
F3 ,50	34796
8.39	34804
P = 0.0001 ; Fig. 2E	34810
P = 0.0001	34810
P	34810
0.0001	34814
Fig. 2E	34822
panel ; F3 ,42 = 12.22 , P < 0.0001 ; Fig. 2F ,	34836
panel ; F3 ,42 = 12.22	34836
panel	34836
F3 ,42 = 12.22	34843
F3 ,42	34843
12.22	34851
P < 0.0001 ; Fig. 2F	34858
P	34858
0.0001 ; Fig. 2F	34862
0.0001	34862
Fig. 2F	34870
panel	34884
the other hand	34895
the RI for alternating step pattern , used as a measure of global coordination ,	34911
the RI	34911
step pattern	34934
a measure of global coordination	34956
a measure	34956
global coordination	34969
all the groups	35014
injury	35035
one-way	35043
ANOVA : F = 124.1 ,	35051
ANOVA	35051
F = 124.1	35058
F	35058
124.1	35062
P < 0.0001 ; Fig. 2E , right panel ; F = 121.9	35069
P < 0.0001	35069
P	35069
0.0001	35073
Fig. 2E , right panel	35081
Fig. 2E	35081
right panel	35090
F = 121.9	35103
F	35103
121.9	35107
P < 0.0001	35114
P	35114
0.0001	35118
Fig. 2F , right panel	35126
Fig. 2F	35126
right panel	35135
Sensory function	35149
The sensory responses to mechanical and heat noxious stimuli	35166
The sensory responses	35166
mechanical and heat noxious stimuli	35191
mechanical	35191
heat noxious stimuli	35206
the end of the follow-up with Von Frey and Planter algesimetry tests	35245
the end	35245
the follow-up with Von Frey and Planter algesimetry tests	35256
the follow-up	35256
Von Frey and Planter algesimetry tests	35275
The withdrawal thresholds	35329
the pre-operative values	35370
each animal	35399
a decrease	35419
tests	35438
the spinal cord contusion	35450
hyperalgesia -LRB- Fig. 3 -RRB-	35491
hyperalgesia	35491
Fig. 3	35505
There	35514
no significant changes between any of the acute or subacute treatment groups	35525
no significant changes	35525
any of the acute or subacute treatment groups	35556
any	35556
the acute or subacute treatment groups	35563
Electrophysiology	35603
Spinal reflexes	35629
Electrical stimulation	35645
the sciatic nerve evoked in all the animals two consecutive muscle responses	35671
the sciatic nerve	35671
all the animals two consecutive muscle responses	35699
all the animals	35699
two consecutive muscle responses	35715
the M	35749
the H-waves	35760
the end of the follow-up , 6 weeks after injury	35776
the end	35776
the follow-up , 6 weeks after injury	35787
the follow-up	35787
6 weeks after injury	35802
6 weeks	35802
injury	35816
neither the amplitude nor the latency of the M-waves	35824
the amplitude	35832
the latency of the M-waves	35850
the latency	35850
the M-waves	35865
the SCI rats	35906
contrast	35923
the H-wave amplitude	35933
injury -LRB- Fig. 4A -RRB-	35970
injury	35970
Fig. 4A	35978
the H/M amplitude ratio	35994
injury in all animals with respect	36047
injury	36047
all animals with respect	36057
all animals	36057
respect	36074
pre-operative values	36085
hyper-reflexia	36118
one-way	36134
ANOVA : F = 27.52 , P < 0.0001 ; Fig. 4B ,	36142
ANOVA : F = 27.52	36142
ANOVA	36142
F = 27.52	36149
F	36149
27.52	36153
P < 0.0001 ; Fig. 4B	36160
P	36160
0.0001 ; Fig. 4B	36164
0.0001	36164
Fig. 4B	36172
panel ; F = 55.15 , P < 0.0001 ; Fig. 4B , right panel	36186
panel ; F = 55.15	36186
panel	36186
F = 55.15	36193
F	36193
55.15	36197
P < 0.0001 ; Fig. 4B , right panel	36204
P < 0.0001	36204
P	36204
0.0001	36208
Fig. 4B , right panel	36216
Fig. 4B	36216
right panel	36225
This increase	36239
acute MSC than in OEC and VE treated groups	36281
acute MSC than in OEC and VE	36281
acute MSC	36281
OEC and VE	36299
MSC	36326
0 dpo vs. VE -- 0 dpo : Bonferroni t = 2.99	36330
0 dpo vs. VE	36330
0 dpo	36330
vs. VE	36336
0 dpo	36343
0	36343
dpo	36345
Bonferroni t = 2.99	36350
Bonferroni t	36350
2.99	36365
P < 0.05 ; MSC -- 0 dpo vs. OEC -- 0 dpo : Bonferroni t = 3.34	36371
P < 0.05	36371
P <	36371
P	36371
0.05	36375
MSC -- 0 dpo vs. OEC -- 0 dpo	36381
MSC	36381
0 dpo vs. OEC	36385
0 dpo	36385
OEC	36395
0 dpo	36399
Bonferroni t = 3.34	36406
Bonferroni t	36406
3.34	36421
P < 0.01	36427
P <	36427
P	36427
0.01	36431
subacute MSC	36445
VE groups	36463
MSC -- 7 dpo vs. VE -- 7 dpo : Bonferroni t = 3.33 , P < 0.05 ; Fig. 4B	36474
MSC	36474
7 dpo vs. VE -- 7 dpo : Bonferroni t = 3.33 , P < 0.05 ; Fig. 4B	36479
7 dpo vs. VE	36479
7 dpo	36479
vs. VE	36485
7 dpo	36492
7	36492
dpo	36494
Bonferroni t = 3.33 , P < 0.05	36499
Bonferroni t = 3.33 , P <	36499
Bonferroni t	36499
= 3.33 , P <	36512
3.33 , P	36514
3.33	36514
P	36520
0.05	36524
Fig. 4B	36530
Fig.	36530
4B	36535
Motor-evoked potentials	36540
the injury , MEPs	36573
the injury	36573
MEPs	36585
a single wave	36607
a mean latency of ~ 8	36627
a mean latency	36627
~ 8	36645
~ 6 and ~ 6 ms	36649
amplitude of ~ 0.22 , ~ 14 and ~ 8.1 mV ,	36672
amplitude	36672
~ 0.22 , ~ 14 and ~ 8.1 mV ,	36685
~ 0.22	36685
~ 14 and ~ 8.1 mV	36692
PL , TA and GM muscles , respectively -LRB- Fig. 4C -RRB-	36712
PL , TA and GM muscles , respectively	36712
PL	36712
TA and GM muscles	36716
Fig. 4C	36749
all the injured rats	36762
the MEP	36783
the follow-up	36812
only a few animals	36831
a very small response -LRB- < 50 lV -RRB-	36860
a very small response	36860
< 50 lV	36883
<	36883
50 lV	36885
the normal latency	36895
42 dpo -LRB- Fig. 4D -RRB-	36917
42 dpo	36917
Fig. 4D	36925
A late MEP response -LRB- latency ~ 20 ms -RRB- and polyphasic	36935
A late MEP response -LRB- latency ~ 20 ms -RRB-	36935
A late MEP response	36935
latency ~ 20 ms	36956
latency ~	36956
20 ms	36965
polyphasic	36976
injury	37002
TA and GM muscles	37012
Fig. 4D and E	37031
Fig. 4D	37031
E	37043
the acute treatment groups	37050
the mean amplitude of this second component	37078
the mean amplitude	37078
this second component	37100
MSC	37136
OEC and VE groups	37145
MSC	37164
0 dpo vs. VE -- 0 dpo : Bonferroni t = 2.85	37168
0 dpo vs. VE	37168
0 dpo	37168
vs. VE	37174
0 dpo	37181
0	37181
dpo	37183
Bonferroni t = 2.85	37188
Bonferroni t	37188
= 2.85	37201
P < 0.05 ; MSC -- 0 dpo vs. OEC -- 0 dpo : Bonferroni t = 2.94	37209
P < 0.05	37209
P <	37209
P	37209
0.05	37213
MSC -- 0 dpo vs. OEC -- 0 dpo	37219
MSC	37219
0 dpo vs. OEC	37223
0 dpo	37223
OEC	37233
0 dpo	37237
Bonferroni t = 2.94	37244
Bonferroni t	37244
= 2.94	37257
P < 0.05 ; Fig. 4F	37265
P < 0.05	37265
P <	37265
P	37265
0.05	37269
Fig. 4F	37275
Fig.	37275
4F	37280
the other hand	37288
the mean amplitude	37313
the delayed VE group compared with both MSC	37346
the delayed VE group	37346
both MSC	37381
7 dpo and OEC	37390
7 dpo	37390
OEC	37400
7 dpo groups in the GM muscle	37404
7 dpo groups	37404
the GM muscle	37420
no statistical differences	37435
groups	37481
Histological results	37489
the effect of cell transplantation	37531
the effect	37531
cell transplantation	37545
the damaged spinal cord tissue	37569
we	37601
the whole amount	37615
spared tissue	37635
the neuronal survival	37650
the reactivity of both astroglial and microglial cells at 42 dpo	37677
the reactivity	37677
both astroglial and microglial cells at 42 dpo	37695
both astroglial and microglial cells	37695
42 dpo	37735
all these analyses	37746
we	37765
the acute and subacute transplant groups	37790
the acute transplants -LRB- Fig. 5A -RRB-	37835
the acute transplants	37835
Fig. 5A	37858
the amount of spinal cord	37868
the amount	37868
spinal cord	37882
tissue	37901
the two cell-treated groups	37922
the vehicle-injected group	37958
two-way ANOVA : F2 ,399 = 44.82 , P	37986
two-way ANOVA : F2 ,399 = 44.82	37986
two-way ANOVA	37986
F2 ,399 = 44.82	38001
F2 ,399	38001
44.82	38010
P	38017
0.0001	38021
MSC injection	38045
more tissue	38083
both rostral and caudal areas	38098
rostral	38103
caudal areas	38115
the epicenter	38131
the OEC grafted	38149
the OEC	38149
group tissue preservation	38165
the caudal region	38215
The same analysis for subacute transplants -LRB- Fig. 5B -RRB-	38234
The same analysis for subacute transplants	38234
The same analysis	38234
subacute transplants	38256
Fig. 5B	38278
a higher percentage of spared tissue	38299
a higher percentage	38299
spared tissue	38322
cell-treated groups	38344
the control	38372
significant differences in rostral	38390
significant differences	38390
rostral	38417
caudal segments between 1 and 2	38429
caudal segments	38429
1 and 2	38453
the epicenter	38469
two-way ANOVA : F2 ,304 = 40.63 , P	38484
two-way ANOVA : F2 ,304 = 40.63	38484
two-way ANOVA	38484
F2 ,304 = 40.63	38499
F2 ,304	38499
40.63	38508
P	38515
0.0001	38519
the center of the injury	38531
the center	38531
the injury	38545
the epicenter	38564
there	38579
no differences between groups in the amount of spared tissue	38590
no differences	38590
groups in the amount of spared tissue	38613
groups	38613
the amount of spared tissue	38623
the amount	38623
spared tissue	38637
acute and delayed treatment	38663
the percentage of spared tissue volume	38692
the percentage	38692
spared tissue volume	38710
Fig. 5C	38747
The results	38757
a similar amount	38774
protected tissue	38794
acute and delayed injection	38819
vehicle -LRB- VE -- 0 dpo : 72.8 ± 2.8 % ; VE -- 7 dpo : 72.7 ± 2.2 % -RRB-	38850
vehicle	38850
VE	38859
0 dpo : 72.8 ± 2.8 % ; VE -- 7 dpo : 72.7 ± 2.2 %	38862
0 dpo	38862
72.8 ± 2.8 % ; VE -- 7 dpo : 72.7 ± 2.2 %	38869
72.8 ± 2.8 %	38869
72.8	38869
2.8 %	38876
VE -- 7 dpo	38882
VE	38882
7 dpo	38885
72.7 ± 2.2 %	38892
72.7	38892
2.2 %	38899
MSC -LRB- MSC -- 0 dpo : 83.8 ± 2.8 % ; MSC -- 7 dpo : 80.8 ± 2.6 % -RRB-	38906
MSC	38906
MSC	38911
0 dpo : 83.8 ± 2.8 % ; MSC -- 7 dpo : 80.8 ± 2.6 %	38915
0 dpo	38915
83.8 ± 2.8 % ; MSC -- 7 dpo : 80.8 ± 2.6 %	38922
83.8 ± 2.8 %	38922
83.8	38922
2.8 %	38929
MSC -- 7 dpo	38935
MSC	38935
7 dpo	38939
80.8 ± 2.6 %	38946
80.8	38946
2.6 %	38953
OEC -LRB- OEC -- 0 dpo : 80.4 ± 2.8 % ; OEC -- 7 dpo : 85.1 ± 2.4 % -RRB-	38963
OEC	38963
OEC	38968
0 dpo : 80.4 ± 2.8 % ; OEC -- 7 dpo : 85.1 ± 2.4 %	38972
0 dpo	38972
80.4 ± 2.8 % ; OEC -- 7 dpo : 85.1 ± 2.4 %	38979
80.4 ± 2.8 %	38979
80.4	38979
2.8 %	38986
OEC -- 7 dpo	38992
OEC	38992
7 dpo	38997
85.1 ± 2.4 %	39004
85.1	39004
2.4 %	39011
respect to neuron survival	39023
respect	39023
neuron survival	39034
the number of NeuN + cells in the two ventral horns of each analysed section	39051
the number	39051
NeuN + cells in the two ventral horns of each analysed section	39065
NeuN + cells	39065
the two ventral horns of each analysed section	39080
the two ventral horns	39080
each analysed section	39105
Fig. 6A	39140
Higher numbers of NeuN + cells	39150
Higher numbers	39150
NeuN + cells	39168
NeuN	39168
cells	39174
the treated groups	39194
both acute and subacute transplantation time vs. the respective control groups	39216
both acute and subacute transplantation time	39216
the respective control groups	39265
the acute transplants -LRB- Fig. 6B -RRB-	39299
the acute transplants	39299
Fig. 6B	39322
both cell types	39332
neurons	39361
both rostral and caudal segments	39372
both rostral	39372
caudal segments	39389
the distal transplantation site	39412
two-way ANOVA : F2 ,300 = 5.69	39445
two-way ANOVA	39445
F2 ,300 = 5.69	39460
F2 ,300	39460
5.69	39469
P < 0.038	39475
P	39475
< 0.038	39477
<	39477
0.038	39479
the case of subacute transplants -LRB- Fig. 6C -RRB-	39490
the case	39490
subacute transplants -LRB- Fig. 6C -RRB-	39502
subacute transplants	39502
Fig. 6C	39524
this neuroprotective effect	39534
caudal	39580
the epicenter -LRB- twoway ANOVA : F2 ,282 = 13.52 , P < 0.0001 -RRB-	39590
the epicenter	39590
twoway ANOVA : F2 ,282 = 13.52 , P	39605
twoway ANOVA : F2 ,282 = 13.52	39605
twoway ANOVA	39605
F2 ,282 = 13.52	39619
F2 ,282	39619
13.52	39628
P	39635
0.0001	39639
more neurons	39657
the distal injection segments	39686
no labeled neurons	39717
the epicenter of the injury in any experimental group	39750
the epicenter	39750
the injury in any experimental group	39767
the injury	39767
any experimental group	39781
injury	39811
a larger cord area	39818
astrocytes in the white matter at the epicenter section	39853
astrocytes	39853
the white matter at the epicenter section	39867
the white matter	39867
the epicenter section	39887
both distal segments	39917
The fraction of GFAP-labeled area	39939
The fraction	39939
GFAP-labeled area	39955
all the groups	39988
the acute -LRB- Fig. 7B -RRB- or subacute -LRB- Fig. 7C -RRB-	40021
the acute	40021
Fig. 7B	40032
subacute	40044
Fig. 7C	40054
transplantation	40063
the area occupied by Iba1-labeled microglia/macrophages	40091
the area	40091
Iba1-labeled microglia/macrophages	40112
the epicenter	40161
the distal sections	40183
acute transplantation -LRB- Fig. 8B -RRB-	40210
acute transplantation	40210
Fig. 8B	40233
a significant reduction of Iba1-labeled area	40243
a significant reduction	40243
Iba1-labeled area	40270
both MSC and OEC treated groups	40305
both MSC	40305
OEC treated groups	40318
comparison	40340
the vehicle group	40356
the caudal section	40377
MSC	40397
0 dpo	40401
VE	40411
0 dpo	40415
Bonferroni t = 2.62 , P < 0.05	40422
Bonferroni t = 2.62 , P <	40422
Bonferroni t	40422
= 2.62 , P <	40435
2.62 , P	40437
2.62	40437
P	40443
0.05	40447
OEC	40453
0 dpo vs. VE	40457
0 dpo	40457
vs. VE	40463
0 dpo	40470
Bonferroni t = 2.69	40477
Bonferroni t	40477
= 2.69	40490
P < 0.05	40498
P <	40498
P	40498
0.05	40502
the other hand	40512
subacute treatment -LRB- Fig. 8C -RRB-	40534
subacute treatment	40534
Fig. 8C	40554
this reduction in the Iba1 + area	40563
this reduction	40563
the Iba1 + area	40581
the Iba1	40581
area	40591
both rostral	40612
MSC	40626
7 dpo	40630
VE	40640
7 dpo	40643
Bonferroni t = 2.51 , P < 0.05	40650
Bonferroni t = 2.51 , P <	40650
Bonferroni t	40650
= 2.51 , P <	40663
2.51 , P	40665
2.51	40665
P	40671
0.05	40675
OEC	40681
7 dpo vs. VE	40685
7 dpo	40685
vs. VE	40691
7 dpo	40698
Bonferroni t = 3.63	40705
Bonferroni t	40705
3.63	40720
P < 0.01	40726
P <	40726
P	40726
0.01	40730
caudal sections	40740
MSC	40757
7 dpo	40761
VE	40771
7 dpo	40774
Bonferroni t = 2.93 , P < 0.05	40781
Bonferroni t = 2.93 , P <	40781
Bonferroni t	40781
= 2.93 , P <	40794
2.93 , P	40796
2.93	40796
P	40802
0.05	40806
OEC	40812
7 dpo vs. VE	40816
7 dpo	40816
vs. VE	40822
7 dpo	40829
Bonferroni t = 2.52	40836
Bonferroni t	40836
= 2.52	40849
P < 0.05	40857
P <	40857
P	40857
0.05	40861
All these results	40868
transplantation of MSCs or OECs	40900
transplantation	40900
MSCs or OECs	40919
the evolution of the injury	40939
the evolution	40939
the injury	40956
the amount of damaged tissue , neuronal death and microglial/macrophage reaction	40977
the amount	40977
damaged tissue , neuronal death and microglial/macrophage reaction	40991
damaged tissue , neuronal death	40991
microglial/macrophage reaction	41026
no statistical differences	41072
type of cells in any of the histological analyses	41118
type	41118
cells in any of the histological analyses	41126
cells	41126
any of the histological analyses	41135
any	41135
the histological analyses	41142
Discussion Cell therapy for SCI	41170
Discussion Cell therapy	41170
SCI	41198
a widely debatable issue	41205
some experimental studies	41239
therapeutic effects	41276
other	41297
no significant improvement	41312
the appearance	41348
undesirable secondary effects	41366
Sykov	41397
a et al. , 2006	41403
a et al.	41403
2006	41413
Sahni & Kessler , 2010	41419
Sahni & Kessler	41419
2010	41436
Hern andez et al. , 2011	41442
Hern andez	41442
et al. , 2011	41453
et al.	41453
2011	41461
Mothe & Tator , 2012	41467
Mothe & Tator	41467
2012	41482
Several factors	41489
the potential therapeutic benefit of cell grafts	41519
the potential therapeutic benefit	41519
cell grafts	41556
a SCI	41578
the nature	41593
the cells , age and donor variation	41607
injury type and severity	41643
cell culture methods	41669
cell delivery methods	41691
the specific techniques	41718
the outcomes	41759
it	41785
published works	41811
different laboratories	41832
this context	41859
we	41873
the effects	41893
MSC and OEC transplantation , two of the most promising cell types	41908
MSC and OEC transplantation	41908
two of the most promising cell types	41937
two	41937
the most promising cell types	41944
SCI repair	41978
the best option for spinal cord contusion injuries	42012
the best option	42012
spinal cord contusion injuries	42032
The results of this study	42064
The results	42064
this study	42079
a similar amount	42095
tissue protection and neuronal survival provided by grafted MSCs and OECs	42115
tissue protection	42115
neuronal survival provided by grafted MSCs and OECs	42137
neuronal survival	42137
grafted MSCs and OECs	42167
acute and subacute treatments	42198
the increased tissue preservation	42244
significant improvement in functional outcomes	42301
significant improvement	42301
functional outcomes	42328
the animals treated with OECs	42351
the animals	42351
OECs	42376
The engraftment with MSCs	42382
The engraftment	42382
MSCs	42403
higher hyper-reflexia	42416
the acute transplant	42451
the animals	42476
higher speed treadmill running and recovery of MEPs	42496
higher speed treadmill running	42496
higher speed treadmill	42496
recovery of MEPs	42531
recovery	42531
MEPs	42543
the grafted cell survival study	42562
a fast reduction	42603
2 -- 3 weeks of both MSCs and OECs	42629
2	42629
3 weeks of both MSCs and OECs	42631
3 weeks	42631
both MSCs and OECs	42642
the injured spinal cord	42668
Thoracic SCI by a moderate contusion	42693
Thoracic SCI	42693
a moderate contusion	42709
a drastic destruction	42739
the spinal cord	42764
practically all the parenchyma at the epicenter	42797
practically all the parenchyma	42797
the epicenter	42831
tissue damage	42857
several spinal cord segments	42877
This affectation	42907
the transmission of the motor-descending information	42933
the transmission	42933
the motor-descending information	42953
the abolition of MEPs	42999
the abolition	42999
MEPs	43016
marked locomotor deficits	43035
a reduced score	43079
the BBB scale	43098
the overground walking skills	43126
the rats -LRB- Basso et al. , 1995 -RRB-	43159
the rats	43159
Basso	43169
et al. , 1995	43175
et al.	43175
1995	43183
a decrease	43190
the speed	43204
a treadmill and uncoordinated locomotor pattern	43225
McEwen & Springer , 2006 ; Redondo-Castro et al. , 2013	43274
McEwen & Springer	43274
2006 ; Redondo-Castro et al.	43293
2006	43293
Redondo-Castro et al.	43299
Redondo-Castro	43299
et al.	43314
2013	43322
The partial protection	43329
spinal cord tissue by MSC or OEC transplantation after the injury	43355
spinal cord tissue	43355
MSC or OEC transplantation after the injury	43377
MSC or OEC transplantation	43377
the injury	43410
improved recovery of overground locomotion or gait coordination	43442
improved recovery	43442
overground locomotion or gait coordination	43463
Only an improvement in the running speed	43507
Only an improvement	43507
the running speed	43530
the acute MSC	43564
transplanted rats	43578
The slight enhancement of motor performance provided by the acute MSC graft	43597
The slight enhancement	43597
motor performance provided by the acute MSC graft	43623
motor performance	43623
the acute MSC graft	43653
the recovery of responses	43691
the recovery	43691
responses	43707
MEPs observed in these animals	43720
MEPs	43720
these animals	43737
this recovery of MEPs	43766
this recovery	43766
MEPs	43783
comparison	43799
intact animals	43813
the BBB score achieved by the acute MSC treated group	43833
the BBB score	43833
the acute MSC treated group	43859
the acute MSC	43859
group	43881
the other groups	43902
A 200-Kdyn contusion injury	43920
the ventral and lateral funiculi	43957
the white matter -LRB- Cao et al. , 2005 -RRB-	43993
the white matter	43993
Cao	44011
et al. , 2005	44015
et al.	44015
2005	44023
The ventrolateral white matter	44030
descending pathways	44070
the control of hindlimb motor function	44104
the control	44104
hindlimb motor function	44119
the reticulospinal tract	44147
Jones & Yang	44173
1985	44187
locomotion and MEP responses	44228
Magnuson et al. , 1999 ; Loy et al. , 2002 ; Cao et al. , 2005	44258
Magnuson	44258
et al. , 1999 ; Loy et al. , 2002 ; Cao et al. , 2005	44267
et al. , 1999	44267
et al.	44267
1999	44275
Loy et al. , 2002	44281
Loy	44281
et al. , 2002	44285
et al.	44285
2002	44293
Cao et al. , 2005	44299
Cao	44299
et al. , 2005	44303
et al.	44303
2005	44311
our study	44321
MSC or OEC transplantation	44332
cord tissue preservation at the center of the injury	44388
cord tissue preservation	44388
the center of the injury	44416
the center	44416
the injury	44430
the ventrolateral white matter	44456
the gross locomotion performance	44527
the other hand	44564
SCI	44580
an amplification of the spinal reflex activity in segments	44592
an amplification	44592
the spinal reflex activity in segments	44612
the spinal reflex activity	44612
segments	44642
the lesion	44661
This hyper-reflexia	44673
a consequence	44696
the loss	44713
inhibitory descending pathways -LRB- Calancie et al. , 1993 -RRB-	44725
inhibitory descending pathways	44725
Calancie	44757
et al. , 1993	44766
et al.	44766
1993	44774
changes in spinal neurons excitability -LRB- Chen et al. , 2001 -RRB-	44784
changes	44784
spinal neurons excitability -LRB- Chen et al. , 2001 -RRB-	44795
spinal neurons excitability	44795
Chen	44824
et al. , 2001	44829
et al.	44829
2001	44837
Transplantation of MSC , independently of the time of injection ,	44844
Transplantation	44844
MSC	44863
the time of injection	44885
the time	44885
injection	44897
higher hyper-reflexia	44916
OEC transplanted	44946
OEC	44946
control injured rats	44970
The increase in spinal reflexes	44992
The increase	44992
spinal reflexes	45008
the recovery of locomotion	45042
the recovery	45042
locomotion	45058
SCI -LRB- Pearson , 2001 -RRB-	45075
SCI	45075
Pearson	45080
2001	45089
fact	45099
functional recovery after incomplete SCI	45105
functional recovery	45105
incomplete SCI	45131
the increase of spinal H reflex responses -LRB- Lee et al. , 2005 -RRB-	45168
the increase	45168
spinal H reflex responses -LRB- Lee et al. , 2005 -RRB-	45184
spinal H reflex responses	45184
Lee	45211
et al. , 2005	45215
et al.	45215
2005	45223
treadmill conditions	45236
the activation of afferent inputs	45258
the activation	45258
afferent inputs	45276
the locomotion movements in spinalized animals -LRB- Whelan , 1996 -RRB-	45301
the locomotion movements	45301
spinalized animals -LRB- Whelan , 1996 -RRB-	45329
spinalized animals	45329
Whelan	45349
1996	45357
the exacerbated hyper-reflexia	45370
the sensitivity of spinal circuitries	45414
the sensitivity	45414
spinal circuitries	45433
afferent inputs	45455
better locomotion recovery -LRB- Lee et al. , 2005 ; Joon et al. , 2009 -RRB-	45482
better locomotion recovery	45482
Lee	45510
et al. , 2005 ; Joon et al. , 2009	45514
et al.	45514
2005 ; Joon et al.	45522
2005	45522
Joon et al.	45528
Joon	45528
et al.	45533
2009	45541
The increased hyper-reflexia	45548
the acute MSC grafted rats together with the partial recovery of MEPs	45580
the acute MSC	45580
rats	45602
the partial recovery of MEPs	45621
the partial recovery	45621
MEPs	45645
the improvement of these animals	45662
the improvement	45662
these animals	45681
the treadmill testing	45698
the sensory perception	45731
no differences between treatments	45755
no differences	45755
treatments	45778
the algesimetry tests	45803
the cell grafts	45835
the increased hyperalgesia	45866
injury	45899
they	45907
hypersensitivity	45929
mechanical and thermal stimuli	45949
respect	45985
injured rats	46004
a detrimental effect	46018
other cell types such as neural stem cells -LRB- Hofstetter et al. , 2005 -RRB-	46053
other cell types	46053
neural stem cells -LRB- Hofstetter et al. , 2005 -RRB-	46078
neural stem cells	46078
Hofstetter	46097
et al. , 2005	46108
et al.	46108
2005	46116
The histological results	46123
the transplantation of MSCs or OECs after SCI	46158
the transplantation	46158
MSCs or OECs after SCI	46181
MSCs or OECs	46181
SCI	46200
tissue damage	46231
more	46259
tissue and neuronal survival of some segments both distal and rostral	46271
tissue and neuronal survival of some segments	46271
tissue and neuronal survival	46271
some segments	46303
distal and rostral	46322
distal	46322
rostral	46333
the epicenter of the injury	46346
the epicenter	46346
the injury	46363
There	46375
no significant differences between acute and subacute cell transplants	46386
no significant differences	46386
acute and subacute cell transplants	46421
the lesion epicenter	46475
the cord tissue	46496
all the SCI groups	46539
the SCI groups	46543
the SCI	46543
groups	46551
the number of engrafted cells into the epicenter	46565
the number	46565
cells	46589
the epicenter	46600
the tissue damage	46648
Some studies	46667
MSC	46695
Ankeny	46700
et al. , 2004	46707
et al.	46707
2004	46715
Isele et al. , 2007	46721
Isele	46721
et al. , 2007	46727
et al.	46727
2007	46735
Abrams et al. , 2009	46741
Abrams	46741
et al. , 2009	46748
et al.	46748
2009	46756
Boido et al. , 2012	46762
Boido	46762
et al. , 2012	46768
et al.	46768
2012	46776
Quertainmont et al. , 2012	46782
Quertainmont	46782
et al. , 2012	46795
et al.	46795
2012	46803
OEC	46813
Verd u et al. , 2003	46818
Verd u	46818
et al.	46825
2003	46833
Garc ıa-Al	46839
et al. , 2004	46854
et al.	46854
2004	46862
transplants	46868
tissue protection	46886
SCI	46910
others	46919
this effect	46939
Takami	46952
et al. , 2002 ; Collazos-Castro et al. , 2005 ; Nandoe Tewarie et al. , 2009	46959
et al. , 2002	46959
et al.	46959
2002	46967
Collazos-Castro et al. , 2005	46973
Collazos-Castro	46973
et al. , 2005	46989
et al.	46989
2005	46997
Nandoe Tewarie et al. , 2009	47003
Nandoe Tewarie	47003
et al. , 2009	47018
et al.	47018
2009	47026
The different types of lesion	47033
The different types	47033
lesion	47056
these discrepancies	47089
tissue preservation	47123
a higher number of neurons	47144
a higher number	47144
neurons	47163
cell transplantation	47186
areas surrounding the epicenter	47210
areas	47210
the epicenter	47228
The neuroprotection provided by the engrafted cells	47243
The neuroprotection	47243
the engrafted cells	47275
the	47275
cells	47289
an indirect effect	47304
paracrine action	47340
secretion of trophic factors	47362
secretion	47362
trophic factors	47375
both MSCs and OECs -LRB- Franssen et al. , 2007 ; Wright et al. , 2011 -RRB-	47394
both MSCs and OECs	47394
Franssen	47414
et al. , 2007 ; Wright et al. , 2011	47423
et al.	47423
2007 ; Wright et al.	47431
2007	47431
Wright et al.	47437
Wright	47437
et al.	47444
2011	47452
the survival of neurons in the segments of the thoracic injury	47478
the survival	47478
neurons in the segments of the thoracic injury	47494
neurons	47494
the segments of the thoracic injury	47505
the segments	47505
the thoracic injury	47521
low relevance for the locomotor performance	47554
low relevance	47554
the locomotor performance	47572
this neuroprotective action	47599
the autonomic functions controlled by the injured spinal cord segments	47651
the autonomic functions	47651
the injured spinal cord segments	47689
the other hand	47726
we	47742
the reduction	47755
microglia/macrophage reactivity caused by both MSC and OEC transplants	47772
microglia/macrophage reactivity	47772
both MSC and OEC transplants	47814
MSC	47819
OEC transplants	47827
L opez-Vales	47873
et al. , 2004a , b ; Chuah et al. , 2011 ; Nakajima et al. , 2012	47886
et al.	47886
2004a , b ; Chuah et al. , 2011 ; Nakajima et al.	47894
2004a , b	47894
2004a	47894
b	47900
Chuah et al. , 2011	47903
Chuah	47903
et al. , 2011	47909
et al.	47909
2011	47917
Nakajima et al.	47923
Nakajima	47923
et al.	47932
2012	47940
This modulatory effect of the grafted cells	47947
This modulatory effect	47947
the grafted cells	47973
reduction of detrimental inflammatory reaction and secretion of cytokines	48005
reduction	48005
detrimental inflammatory reaction and secretion	48018
cytokines	48069
the transplantation of MSCs and OECs	48086
the transplantation	48086
MSCs and OECs	48109
the amount of damaged tissue	48143
the amount	48143
damaged tissue	48157
neurons	48197
the spared tissue	48208
the chronic microglial / macrophage presence	48238
the chronic microglial	48238
macrophage presence	48262
Localization of the transplanted cells	48283
Localization	48283
the transplanted cells	48299
similar amounts of MSCs and OECs	48332
similar amounts	48332
MSCs and OECs	48351
the first week	48372
injection	48393
a marked decrease in the GFP signal	48408
a marked decrease	48408
the GFP signal	48429
the two following weeks	48453
the survival of transplanted cells within the spinal cord	48503
the survival	48503
transplanted cells within the spinal cord	48519
transplanted cells	48519
the spinal cord	48545
cell type	48589
the spinal cord environment after contusion	48621
the spinal cord environment	48621
contusion	48655
Barakat	48698
et al. , 2005	48706
et al.	48706
2005	48714
Pearse et al. , 2007	48720
Pearse	48720
et al. , 2007	48727
et al.	48727
2007	48735
Abrams et al. , 2009	48741
Abrams	48741
et al. , 2009	48748
et al.	48748
2009	48756
Nakajima et al. , 2012	48762
Nakajima	48762
et al. , 2012	48771
et al.	48771
2012	48779
immunoprivileged properties of MSCs	48795
immunoprivileged properties	48795
MSCs	48826
Nauta & Fibbe	48847
2009	48862
reduced survival	48869
MSCs	48899
rats	48909
Abrams	48915
et al. , 2009	48922
et al.	48922
2009	48930
human donors	48940
Himes et al. , 2006	48954
Himes	48954
et al.	48960
2006	48968
the limited survival of the OEC transplant	49015
the limited survival	49015
the OEC transplant	49039
contusion injuries	49083
Barakat	49103
et al. , 2005 ; Pearse et al. , 2007	49111
et al.	49111
2005 ; Pearse et al.	49119
2005	49119
Pearse et al.	49125
Pearse	49125
et al.	49132
2007	49140
dorsal column lesion	49150
Roet	49172
et al. , 2012	49177
et al.	49177
2012	49185
a recent work	49195
we	49210
allogenic transplantation of both MSCs and OECs	49224
allogenic transplantation	49224
both MSCs and OECs	49253
the expression of immune rejection-associated genes	49280
the expression	49280
immune rejection-associated genes	49298
acute and delayed transplantation -LRB- Torres-Esp ın et al. , 2013 -RRB-	49338
acute and delayed transplantation	49338
Torres-Esp ın	49373
et al. , 2013	49387
et al.	49387
2013	49395
an immunogenic reaction against these cells	49416
an immunogenic reaction	49416
these cells	49448
More work	49461
work	49466
the reason	49494
the poor grafted cell survival	49509
the poor	49509
cell survival	49526
immunosuppressive co-treatments	49557
our data	49603
no differences	49617
time-survival between MSCs and OECs	49635
time-survival	49635
MSCs and OECs	49657
the survival of the grafted cells	49692
the survival	49692
the grafted cells	49708
the treatment success	49749
this factor	49772
the differences	49801
MSC and OEC transplants	49831
MSC vs. OEC for spinal cord contusion injuries Our findings	49856
MSC vs. OEC	49856
spinal cord contusion injuries Our findings	49872
spinal cord contusion injuries	49872
Our findings	49903
the capacity of both MSC and OEC grafts	49928
the capacity	49928
both MSC and OEC grafts	49944
MSC	49949
OEC grafts	49957
beneficial effects	49979
spinal cord contusion	50004
a number of works	50033
a number	50033
works	50045
tissue sparing and functional recovery	50072
tissue sparing	50072
MSC transplantation	50116
contusion injuries	50142
Chopp	50162
et al. , 2000	50168
et al.	50168
2000	50176
Hofstetter et al. , 2002	50182
Hofstetter	50182
et al. , 2002	50193
et al.	50193
2002	50201
Neuhuber et al. , 2005	50207
Neuhuber	50207
et al. , 2005	50216
et al.	50216
2005	50224
Himes et al. , 2006	50230
Himes	50230
et al. , 2006	50236
et al.	50236
2006	50244
Quertainmont et al. , 2012	50250
Quertainmont	50250
et al. , 2012	50263
et al.	50263
2012	50271
the effects	50278
OEC treatment in the contusion model	50311
OEC treatment	50311
the contusion model	50328
Several studies of acute and delayed OEC transplantation after contusion injury	50349
Several studies	50349
OEC transplantation	50386
contusion injury	50412
no effects	50436
locomotion recovery	50450
Pearson	50471
2001	50480
Takami	50486
et al. , 2002	50493
et al.	50493
2002	50501
Resnick et al. , 2003	50507
Resnick	50507
et al. , 2003	50515
et al.	50515
2003	50523
Barakat et al. , 2005	50529
Barakat	50529
et al. , 2005	50537
et al.	50537
2005	50545
Collazos-Castro et al.	50551
Collazos-Castro	50551
et al.	50567
2005	50575
contrast	50585
complete transection injuries	50601
the effects of OECs on axonal growth and functional improvement	50631
the effects	50631
OECs on axonal growth and functional improvement	50646
OECs	50646
axonal growth and functional improvement	50654
Li et al. , 1998 ; L opez-Vales et al. , 2006 , 2007 ; Franssen et al. , 2007	50722
Li et al.	50722
Li	50722
et al.	50725
1998 ; L opez-Vales et al.	50733
1998	50733
L opez-Vales et al.	50739
L opez-Vales	50739
et al.	50752
2006	50760
2007 ; Franssen et al. , 2007	50766
2007	50766
Franssen et al. , 2007	50772
Franssen	50772
et al. , 2007	50781
et al.	50781
2007	50789
Contusion	50796
the most complex and severe type of lesion to the spinal cord	50809
the most complex and severe type	50809
lesion to the spinal cord	50845
lesion	50845
the spinal cord	50855
the formation	50897
large cystic cavities , extensive hemorrhage and secondary loss of tissue	50914
large cystic cavities	50914
extensive hemorrhage	50937
secondary loss of tissue	50962
secondary loss	50962
tissue	50980
the hostile environment after contusion	51001
the hostile environment	51001
contusion	51031
the graft survival	51063
spinal cord contusion	51092
the most relevant injury model	51128
it	51163
the neuropathology of most human SCIs -LRB- Bunge et al. , 1997 -RRB-	51173
the neuropathology	51173
most human SCIs	51195
Bunge	51212
et al. , 1997	51218
et al.	51218
1997	51226
procurement and expansion	51244
the MSCs , in addition to the better functional effects	51273
the MSCs	51273
the better functional effects	51298
the MSC	51337
groups	51353
them	51366
cell therapy in spinal cord contusion than OECs	51389
cell therapy	51389
spinal cord contusion than OECs	51405
spinal cord contusion	51405
OECs	51432
the early stages of the pathology	51454
the early stages	51454
the pathology	51474
the other hand	51492
the post-injury time of intervention	51508
the post-injury time	51508
intervention	51532
an important point to consider for cell therapy	51548
cell therapy	51583
The earliest times	51597
damage	51645
the tissue -LRB- L opez-Vales et al. , 2006 , 2007 -RRB-	51664
the tissue	51664
L opez-Vales	51676
et al. , 2006 , 2007	51689
et al.	51689
2006	51697
2007	51703
the detrimental ambience during the first days of injury	51719
the detrimental ambience	51719
the first days of injury	51751
the first days	51751
injury	51769
the efficacy of the transplant	51789
the efficacy	51789
the transplant	51805
the clinical application of acute cell transplants	51831
the clinical application	51831
acute cell transplants	51859
Some works	51902
better results	51927
early cell transplantation	51965
Hofstetter	51993
et al. , 2002 ; L opez-Vales et al. , 2006	52004
et al.	52004
2002 ; L opez-Vales et al.	52012
2002	52012
L opez-Vales et al.	52018
L opez-Vales	52018
et al.	52031
2006	52039
another	52050
more positive effects	52068
delayed treatment -LRB- Nandoe Tewarie et al. , 2009 -RRB-	52107
delayed treatment	52107
Nandoe Tewarie	52126
et al. , 2009	52141
et al.	52141
2009	52149
accordance with our present study for the MSC grafts	52158
accordance	52158
our present study for the MSC grafts	52174
our present study	52174
the MSC grafts	52196
the controversial results	52219
the different experimental conditions	52259
the type	52332
cells regarding mechanisms of action	52344
cells	52344
mechanisms of action	52360
mechanisms	52360
action	52374
the time treatment window , the number of cells injected	52382
the time treatment window	52382
the number of cells injected	52409
the number	52409
cells injected	52423
cells	52423
possible combined treatments	52442
the optimal cell therapy strategy for SCI	52507
the optimal cell therapy strategy	52507
SCI	52545
